Minerva Surgical (UTRS) 10-K 22 Mar 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 11, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Trading Symbol	UTRS
Title of 12(b) Security	Common Stock, $ 0.001 par value
Security Exchange Name	NASDAQ
Entity Registrant Name	MINERVA SURGICAL, INC.
Entity Central Index Key	0001452965
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		28,822,283
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE
Entity File Number	001-40919
Entity Tax Identification Number	26-3422906
Entity Address, Address Line One	4255 Burton Dr.
Entity Address, City or Town	Santa Clara
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054
City Area Code	855
Local Phone Number	646-7874
Document Annual Report	true
Document Transition Report	false
Icfr Auditor Attestation Flag	false
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s Proxy Statement for its 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2021.
Auditor Name	BDO USA, LLP
Auditor Location	San Jose, CA
Auditor Firm ID	243

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 40,608	$ 17,359
Restricted cash, current	7,283	7,203
Accounts receivable, net	7,292	8,379
Inventory	15,682	10,201
Prepaid expenses and other current assets	4,139	2,279
Total current assets	75,004	45,421
Restricted cash, net of current portion	524	604
Intangible asset, net	34,970	43,141
Property and equipment, net	4,594	2,880
Total assets	115,092	92,046
Current Liabilities:
Accounts payable	3,629	3,506
Accrued compensation	3,518	2,889
Accrued liabilities	10,473	10,204
Contingent consideration liability, current	5,000
Delayed cash purchase consideration		15,000
Current portion of long-term debt	189	1,668
Total current liabilities	22,809	33,267
Redeemable convertible preferred stock warrant liability		42
Long-term debt	39,085	29,423
Convertible notes (includes $0 at December 31, 2021 and $46.5 million at December 31, 2020, respectively, attributable to related parties)		66,196
Derivative liabilities (includes $0 at December 31, 2021 and $23.6 million at December 31, 2020, respectively, attributable to related parties)		38,007
Contingent consideration liability, net of current portion	9,094	23,667
Total liabilities	70,988	190,602
Commitments and contingencies (Note 9)
Redeemable convertible preferred stock, $0.001 par value, no shares and 121,732,397 shares authorized as of December 31, 2021 and December 31, 2020, respectively; no shares issued and outstanding as of December 31, 2021 and 12,397,838 shares issued and outstanding as of December 31, 2020; liquidation value of $0 as of December 31, 2021 and $136,168 December 31, 2020, respectively		123,255
Stockholders` equity (deficit):
Preferred stock, $0.001 par value, 5,000,000 shares and no shares authorized as of December 31, 2021 and December 31, 2020, respectively; no shares issued and outstanding as of December 31, 2021 and 2020
Common stock, $0.001 par value, 100,000,000 and 144,406,928 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 28,822,283 and 1,192,299 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively	28	1
Additional paid-in capital	293,621	6,269
Accumulated other comprehensive income	11	11
Accumulated deficit	(249,556)	(228,092)
Total stockholders' equity (deficit)	44,104	(221,811)
Total liabilities, redeemable convertible preferred stock, and stockholders’ deficit	$ 115,092	$ 92,046

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Convertible notes payable to related parties	$ 0	$ 46,500
Derivative liabilties related to related parties	$ 0	$ 23,600
Redeemable convertible preferred stock, par value	$ 0.001	$ 0.001
Redeemable convertible preferred stock shares, authorized	0	121,732,397
Redeemable convertible preferred stock shares, issued	0	12,397,838
Redeemable convertible preferred stock shares, outstanding	0	12,397,838
Redeemable convertible preferred stock, liquidation value	$ 0	$ 136,168
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	0
Preferred stock, shares, Issued	0	0
Preferred stock, shares, outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	144,406,928
Common stock, shares, Issued	28,822,283	1,192,299
Common stock, shares, outstanding	28,822,283	1,192,299

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenues	$ 52,103	$ 37,768
Cost of goods sold	21,580	18,648
Gross profit	30,523	19,120
Operating expenses
Sales and marketing	32,193	22,974
General and administrative	22,183	8,212
Research and development	5,292	3,324
Total operating expenses	59,668	34,510
Loss from operations	(29,145)	(15,390)
Interest income	10	81
Interest expense (includes $4.5 million and $4.6 million to related parties in fiscal years 2021 and 2020, respectively)	(11,728)	(12,140)
Change in fair value of derivative liabilities	38,007	8,340
Bargain purchase gain		643
Loss on extinguishment of long-term debt and convertible notes	(21,295)
Gain on forgiveness of PPP loan	3,036
Other income (expense), net	(340)	71
Net Loss before income taxes	(21,455)	(18,395)
Income tax benefit (expense)	(9)	132
Net loss	$ (21,464)	$ (18,263)
Net loss per share attributable to common stockholders, basic and diluted	$ (3.06)	$ (18.85)
Weighted-average common shares used in computing net loss per share, basic and diluted	7,012,226	968,648

Statements of Operations (Paren

Statements of Operations (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Interest Expense, Related Party	$ 4.5	$ 4.6

Statements of Redeemable Conver

Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Balance at Dec. 31, 2019	$ (204,524)		$ 1	$ 5,293	$ 11	$ (209,829)
Temporary Equity, Balance, shares at Dec. 31, 2019		11,066,427
Temporary Equity, Balance at Dec. 31, 2019		$ 120,518
Balance, shares at Dec. 31, 2019			909,486
Issuance of Series D redeemable convertible preferred stock in connection with business combination		$ 2,737
Issuance of Series D redeemable convertible preferred stock in connection with business combination, shares		1,331,411
Issuance of common stock upon exercise of stock options	$ 118			118
Issuance of common stock upon exercise of stock options, shares	282,813		146,781
Issuance of common stock upon early exercise of stock options, shares			136,032
Stock-based compensation expense	$ 858			858
Net loss	(18,263)					(18,263)
Balance at Dec. 31, 2020	$ (221,811)		$ 1	6,269	11	(228,092)
Temporary Equity, Balance, shares at Dec. 31, 2020	12,397,838	12,397,838
Temporary Equity, Balance at Dec. 31, 2020	$ 123,255	$ 123,255
Balance, shares at Dec. 31, 2020			1,192,299
Conversion of Series D redeemable convertible preferred stock warrants into common stock warrants upon initial public offering	370			370
Conversion of Series D redeemable convertible preferred stock into common stock upon initial public offering, shares		(12,397,838)	12,397,838
Conversion of Series D redeemable convertible preferred stock into common stock upon initial public offering	123,255	$ (123,255)	$ 12	123,243
Conversion of 2018, 2019 and 2020 Notes into common stock upon initial public offering	89,303		$ 7	89,296
Conversion of 2018, 2019 and 2020 Notes into common stock upon initial public offering, shares			7,006,228
Issuance of common stock upon initial public offering, net of issuance costs and underwriting discount of $8,414	66,585		$ 6	66,579
Issuance of common stock upon initial public offering, net of issuance costs and underwriting discount of $8,414, shares			6,250,000
Issuance of common stock upon exercise of stock options	$ 975		$ 2	973
Issuance of common stock upon exercise of stock options, shares	1,975,918		1,612,363
Issuance of common stock upon early exercise of stock options, shares			363,555
Vesting of early exercised stock options	$ 74			74
Stock-based compensation expense	6,817			6,817
Net loss	(21,464)					(21,464)
Balance at Dec. 31, 2021	$ 44,104		$ 28	$ 293,621	$ 11	$ (249,556)
Temporary Equity, Balance, shares at Dec. 31, 2021	0
Balance, shares at Dec. 31, 2021			28,822,283

Statements of Redeemable Conv_2

Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Statement Of Stockholders Equity [Abstract]
Net of issuance costs and underwriting discount	$ 8,414

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flows From Operating Activities:
Net loss	$ (21,464)	$ (18,263)
Adjustments to reconcile net loss to net cash used in operating activities:
Bargain purchase gain		(643)
Amortization of debt discount and debt issuance costs	3,348	3,321
Non-cash interest expense from long-term debt and convertible notes	5,842	6,955
Loss on extinguishment of long-term debt and convertible notes	21,295
Depreciation and amortization	10,620	7,076
Gain on forgiveness of PPP loan	(3,036)
Stock-based compensation expense	6,817	858
Change in fair value of redeemable convertible preferred stock warrant liability	328	(33)
Change in fair value of contingent consideration liability	427	(175)
Change in fair value of derivative liabilities	(38,007)	(8,340)
Deferred taxes		(132)
Net changes in operating assets and liabilities, net of acquired businesses:
Accounts receivable, net	1,087	(4,432)
Inventory	(9,072)	1,264
Prepaid expenses and other current assets	(5,025)	(1,064)
Accounts payable	3,300	(687)
Accrued liabilities	532	1,501
Accrued compensation	629	553
Net cash used in operating activities	(22,379)	(12,241)
Cash Flows From Investing Activities:
Cash paid for business combination		(15,000)
Purchase of property and equipment	(584)	(453)
Net cash used in investing activities	(584)	(15,453)
Cash Flows From Financing Activities:
Proceeds from issuance of common stock	975	118
Proceeds from issuance of convertible notes and borrowing under term loans, net of payment of lender fees and costs	39,531	17,959
Proceeds from initial public offering, net of underwriting discount and commission	69,750
Payment of Delayed purchase obligation and Development Milestone	(25,000)
Payment of debt fees	(103)
Payment of Success Fee	(400)
Repayment of term loan	(35,376)
Payment of deferred offering costs	(3,165)
Net cash provided by financing activities	46,212	18,077
Net decrease in cash, cash equivalents and restricted cash	23,249	(9,617)
Cash, cash equivalents and restricted cash at the beginning of the period	25,166	34,783
Cash, cash equivalents and restricted cash at the end of the period	48,415	25,166
Reconciliation of cash, cash equivalents and restricted cash to balance sheets
Cash and cash equivalents	40,608	17,359
Restricted cash	7,807	7,807
Cash, cash equivalents and restricted cash in balance sheets	48,415	25,166
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	2,318	1,799
Cash paid for income taxes	18	4
Supplemental Disclosure of Non-cash Items:
Forgiveness of PPP loan	(3,036)
Conversion of Series D redeemable convertible preferred stock warrants into common stock warrants upon initial public offering	370
Conversion of Series D redeemable convertible preferred stock into common stock upon initial public offering	123,255
Conversion of 2018, 2019 and 2020 Notes into common stock upon initial public offering	89,303
Deferred offering costs reclassified to equity	3,165
Issuance of derivative instruments related to convertible notes		6,848
Fair value of net assets acquired in business combination		57,222
Fair value of contingent consideration in connection to business combination		23,842
Fair value of delayed cash consideration in connection to business combination		15,000
Issuance of Series D redeemable convertible preferred stock in connection to business combination		2,737
Vesting of early exercised stock options	74
Purchases of property and equipment included in accounts payable		6
Net reclassification of inventory to property and equipment for customer usage agreements	$ 3,598	$ 1,150

Formation and Business of the C

Formation and Business of the Company	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block [Abstract]
Formation and Business of the Company	1. Formation and Business of the Company The Company Minerva Surgical, Inc. (the Company) was incorporated in the state of Delaware on November 3, 2008. The Company's headquarters are in Santa Clara, California. The Company is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company commenced commercial introduction of its products in the United States in 2015 following the clearance by the U.S. Food and Drug Administration. In May 2020, the Company acquired certain assets from Boston Scientific Corporation (BSC) to broaden its product offerings to its customers. The Company derives all of its revenue from sales to customers in the United States through a direct sales force. Initial Public Offering On October 21, 2021, the Company's registration statement on Form S-1 (File No. 333- 259832 ) relating to its initial public offering (IPO) of common stock became effective. T he Company issued and sold 6,250,000 shares of its common stock at a public offering price of $ 12.00 per share, for aggregate gross proceeds of $ 75.0 million. The Company received $ 69.8 million in net proceeds after deducting underwriting discounts and commissions. The total IPO offering costs other than underwriting discounts and commissions were $ 3.2 million. All expenses incurred in connection with the Company's IPO had been paid as of December 31, 2021. In connection with the completion of its IPO, on October 21, 2021, the Company's certificate of incorporation was amended and restated to provide for 100,000,000 authorized shares of common stock with a par value of $ 0.001 per share and 5,000,000 authorized shares of preferred stock with a par value of $ 0.001 per share. Immediately prior to the IPO, $ 79.2 million in aggregate outstanding principal and accrued interest of the convertible notes converted into 7,006,228 shares of redeemable convertible preferred stock at a conversion price of $ 11.31 per share. Also, immediately prior to the closing, all outstanding shares of the Company's redeemable convertible preferred stock (including those issued upon conversion of the convertible notes) converted into 19,404,066 shares of common stock which resulted in the reclassification of the c arrying value of the preferred stock to common stock and additional paid-in capital. Liquidity The Company incurred a net loss of $ 21.5 million and $ 18.3 million during the years ended December 31, 2021 and 2020, respectively, and had an accumulated deficit of $ 249.6 million as of December 31, 2021. T he Company had cash and cash equivalents of $ 40.6 million as of December 31, 2021. The Company has incurred significant operational losses since inception and expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Historically, the Company’s activities have been financed through private placements of equity securities and debt . On October 21, 2021, the Company completed an IPO and received approximately $ 69.8 million in net proceeds after deducting underwriting discounts and commissions. Management believes that the Company’s existing cash and cash equivalents allow the Company to finance its operations for at least the next 12 months from the date of issuance of these financial statements. Impact of the COVID-19 pandemic The COVID-19 pandemic and the resulting economic downturn have impacted business conditions in the industry in which the Company operates. Beginning in March 2020, the Company’s net sales were negatively impacted by the COVID-19 pandemic as hospitals and ambulatory surgical centers (ASCs) delayed or canceled elective procedures. In response to the pandemic, many state and local governments in the U.S. issued orders that temporarily precluded elective procedures in order to conserve scarce health system resources. The decrease in hospital and ASCs admission rates and elective surgeries reduced both the number of patients being evaluated for treatment with and demand for elective procedures using the Company's products. In March 2020, the governor of California, where the Company’s headquarters are located, issued “stay at home” orders limiting non-essential activities, travel and business operations. Such orders or restrictions have resulted in reduced operations at the Company’s headquarters (including manufacturing facility), work stoppages, slowdowns and delays, travel restrictions and cancellation of events and have restricted the efforts of the Company’s sales representatives, thereby significantly and negatively impacting the Company’s operations. These orders and restrictions have significantly decreased the number of procedures performed using the Company’s products and otherwise negatively impacted sales and operations. The Company experienced a second wave of slower than expected revenue growth in the second half of 2021 when certain state governments responding to a second wave of COVID-19 infection rates, reinstated hospital and ASC closures for elective procedures. The Company has taken necessary precautions to safeguard its employees, patients, customers, and other stakeholders from the COVID-19 pandemic, while maintaining business continuity to support its patients, customers and employees. The timing, extent and continuation of any increase in procedures, and any corresponding increase in sales of the Company’s products, and whether there could be a future decrease in the current level of procedures as a result of the COVID-19 pandemic or otherwise, remain uncertain and are subject to a variety of factors. The Company is continuing to monitor the impact of the COVID-19 pandemic on its employees and customers and on the markets in which it operates and will take further actions that the Company considers prudent to address the COVID-19 pandemic, while ensuring that it can support its customers and continue to develop its products. The ultimate extent of the impact of the COVID-19 pandemic on the Company is highly uncertain and subject to change. This impact may result in a material, adverse impact on liquidity, capital resources, supply chain, operations and revenue and may affect third parties in which the Company relies and could worsen over time. The extent of the continuing resurgence of COVID-19, the efficacy and extent of distribution of vaccines, and the impact of variants of COVID-19 is unpredictable.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of presentation The accompanying financial statements have been prepared using accounting principles generally accepted in the United States of America (GAAP). Reverse Stock Split On October 14, 2021, the Company effected a 1 -for-6.046 reverse stock split of its outstanding common stock and redeemable convertible preferred stock. Upon the effectiveness of the reverse stock split, all issued and outstanding shares of common stock options to purchase common stock, warrants, instruments convertible to shares, redeemable convertible preferred stock and related share data and per share amounts contained in the accompanying financial statements were retroactively revised to reflect this reverse stock split for all periods presented. The par value of the authorized stock was not adjusted as a result of the reverse stock split. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Significant estimates and assumptions include accounts receivable allowances, inventory allowances, recoverability of long-term assets, valuation of equity instruments and equity-linked instruments, valuation of common stock, stock-based compensation, valuation of the redeemable convertible preferred stock warrant liability and derivative liabilities, valuation and estimated useful lives of intangible assets, deferred tax assets and related valuation allowances, and impact of contingencies. Segments The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Fair value of financial instruments The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and restricted cash, accounts receivable, accounts payable, and accrued liabilities, approximate their fair value due to the short-term nature of these assets and liabilities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loans approximate their fair values and is classified as a Level 2 liability. Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (FDIC) insured limits. The Company earns revenue from sale of disposable devices and controllers to customers such as hospitals, ACS and physician offices. The Company’s accounts receivable are derived from revenue earned from customers. The Company performs ongoing credit evaluations of its customers’ financial condition and generally requires no collateral from its customers. As of December 31, 2021 and 2020, and for the years then ended, no customer accounted for more than 10% of accounts receivable or revenue. Concentration of suppliers The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect results of operations; however, management believes that suitable replacement suppliers could be obtained in such an event. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents, which include money market funds. Restricted cash As of December 31, 2021 and 2020, cash of $ 7.8 million was restricted from withdrawal. Restricted cash consists of collateral for letters of credit issued in connection with litigation, real estate leases, and corporate credit cards (See Note 9). Accounts receivable and allowances Accounts receivable are generally from hospitals and ASCs and are stated at amounts billed less allowances for doubtful accounts. The Company continually monitors customer payments and maintains an allowance for estimated losses resulting from a customer’s inability to make required payments. The Company considers factors such as historical experience, credit quality, age of the accounts receivable balances, geographic-related risks and economic conditions that may affect a customer’s ability to pay. Accounts receivable are written off when the Company deems individual balances are no longer collectible. As of December 31, 2021 and 2020, accounts receivable is presented net of an allowance for doubtful accounts of $ 0.5 million and $ 0.4 million, respectively. For the years ended December 31, 2021 and 2020, the Company recorded a provision for bad debts of less than $ 0.2 million and $ 0.3 million, respectively . Inventory Inventory consist primarily of disposable devices, controllers, and components as raw materials and finished goods and are stated at the lower of cost or net realizable value. Cost is determined using standard cost based on the first-in, first-out method (FIFO) for all inventories. The Company periodically assesses the recoverability of all inventories to determine whether adjustments for impairment are required. The Company evaluates the related commercial mix of finished goods and other general obsolescence and impairment criteria in assessing the recoverability of the Company’s inventory and records a provision for excess, expired, and obsolete inventory based primarily on estimates of forecasted revenues. A significant change in the timing or level of demand for products as compared to forecasted amounts may result in recording additional provision for excess, expired, and obsolete inventory in the future. For the years ended December 31, 2021 and 2020, the Company did no t record a provision for excess or obsolete inventory. Property and equipment, net Property and equipment is recorded at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the estimated useful lives of the assets ( two to seven years ) or the lease term of the leasehold improvements, whichever is lower. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation and amortization are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period such gain or loss is realized. Intangible assets Intangible assets arising from business combinations, such as trade names, customer relationships and developed technology, are initially recorded at estimated fair value. Amortization is computed over the estimated useful life of each asset on a straight-line basis. The Company determines the useful lives of identifiable intangible assets after considering the facts and circumstances related to each intangible asset. Factors the Company considers when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, the Company’s long-term strategy for using the asset, any laws or other local regulations which could impact the useful life of the asset and other economic factors, including competition and specific market conditions. The useful lives of the major intangible asset classes are as follows: Trademarks 6.5 Developed technology 10 Customer relationships 3 Business combination Business combinations are accounted for under the acquisition method. The Company recognizes the assets acquired and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. Contingent consideration is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using a Monte Carlo simulation. These cash flow projections are discounted with an appropriate risk-adjusted rate. The fair value of the contingent consideration liability is remeasured at each reporting period with the change in the fair value recorded as a component of operating expenses in the statements of operations until the underlying contingency is resolved. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded. The Company assesses the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant estimates and assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset, future cash inflows and outflows, probabilities of success, asset lives, and the appropriate discount rates. The Company uses the income approach to determine the fair value of developed technology acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. The Company bases its revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected product introductions by competitors. Developed technology represents patented and unpatented technology and know-how. The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships and trade names. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names. Any excess fair value of the net tangible and intangible assets acquired over the purchase price is recorded as bargain purchase gain in the statements of operations at the acquisition closing date. During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed. After the measurement period, all adjustments are recorded in the statements of operations as operating expenses or income. Transaction costs and restructuring costs associated with a business combination are expensed as incurred. Impairment of long-lived assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There has been no impairment of long-lived assets during the years ended December 31, 2021 and 2020. Leases The Company leases its facilities and meets the requirements to account for these leases as operating leases. The Company recognizes rent expense on a straight-line basis over the non-cancellable lease term. Where leases contain escalation clauses, rent abatements or concessions, such as rent holidays and landlord or tenant incentives or allowances, the Company applies them in the determination of straight-line rent expense over the lease term. The Company records the difference between the rent paid and the straight-line rent as a deferred rent liability. Redeemable convertible preferred stock The Company records all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because while it is not mandatorily redeemable, in certain events considered not solely within the Company’s control, such as a merger, acquisition or sale of all or substantially all of the Company’s assets (each, a deemed liquidation event), the redeemable convertible preferred stock will become redeemable at the option of the holders of at least a majority of the then-outstanding preferred shares. All outstanding shares of the convertible preferred stock converted into common stock upon effectiveness of the IPO. Redeemable convertible preferred stock warrants and common stock warrants Freestanding preferred stock warrants are accounted for in accordance with Financial Accounting Standard Board (FASB) ASU Topic 480, Distiguishing Liabilities from Equity (ASC 480) and classified as liabilities on the balance sheet because the underlying preferred stock shares are redeemable upon occurrence of a deemed liquidation event. Preferred stock warrants are subject to re-measurement at each balance sheet date with the change in fair value, if any, recognized in other income (expense), net in the statements of operations. All outstanding preferred stock warrants converted into common stock warrants upon effectiveness of the IPO. Upon closing of the IPO, the warrant liability was reclassified to additional paid-in capital as the common stock warrants meet all criteria for equity classification. Derivative liabilities Embedded derivatives that are required to be bifurcated from their host contract are evaluated and valued separately from the debt instrument. Under the Company’s Credit Agreement (the Ares Agreement) with Ares Capital Corporation and Ares Direct Finance I LP (collectively Ares) (Note 8), upon the occurrence of specified prepayment trigger events, including a default or a change in control, the Company may be required to make mandatory prepayments of the borrowings. The prepayment premium is considered an embedded derivative, as the holder of the loan may exercise the option to require prepayment by the Company. The mandatory prepayment derivative liability is recorded at fair value upon entering into the Ares Agreement and is subject to remeasurement to fair value at each balance sheet date, with any changes in fair value recognized in the statements of operations. The Company’s convertible notes contain embedded features (Note 8)—a qualified financing put, non-qualified financing put, and change of control put features—that are bifurcated and accounted for as derivative liabilities and recorded as a debt discount on the note issuance date. Debt discount is reported as a direct deduction to the carrying amount of the convertible notes and amortized using the effective interest rate over the life of the convertible notes as interest expense. The embedded derivative features are recorded at fair value upon entering into the note purchase agreements and are subject to remeasurement to fair value at each balance sheet date, with any changes in fair values recognized in the statements of operations. In connection with execution of the CIBC Agreement, the Company entered into a separate Success Fee Agreement with CIBC (see Note 8). In the event of a sale or other disposition by the Company of all or substantially all of its assets, a merger or consolidation, or an initial public offering (a Liquidity Event), before the termination of the agreement, the Company agreed to pay a fee to CIBC equal to $ 0.4 million (Success Fee) . This agreement has been identified as a freestanding derivative and is subject to remeasurement to its fair value at each reporting date or repayment or expiration, with any changes in fair values recognized in the statements of operations. In connection with the IPO, the derivative liability was settled upon the Company paying the Success Fee of $ 0.4 million to CIBC pursuant to the Success Fee Agreement. Debt discount The Company records the value of original issuance discounts, issuance costs, and discounts attributable to warrants or bifurcated derivatives associated with debt on issuance, as a debt discount, which is presented net of the outstanding balance of debt on the balance sheet and amortized as an adjustment to interest expense over the borrowing term using the effective interest method. Revenue recognition The Company generates revenue primarily from the sale of disposable devices and controllers that treat the root causes of abnormal uterine bleeding (AUB). The Company invoices hospitals, ASCs, and physician offices for the sold products and pays commissions to the sales representatives. The Company also provides controllers to customers under evaluation and long-term placement agreements. Under these agreements, the Company delivers the controller to the customer’s facility without a fee and the customer agrees to purchase disposable products at a stated price over the term of the agreement. The Company retains title to the controllers. The Company, in general, does not enforce a minimum purchase requirement under these agreements. Terms of the long-term placement agreements range from several months to multiple years and may be extended or terminated upon mutual agreement. These types of agreements include an embedded lease, which is generally a cancellable operating lease, for the right to use a controller. The Company also offers extended warranty agreements to customers for controller defects, malfunctions, or system failures. In line with ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies performance obligations. A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party’s rights regarding the products to be transferred and identifies the payment terms related to these products, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. The Company identifies performance obligations in contracts with customers, which may include its products and implied promise to provide the free leased controller. The transaction price is determined based on the amount the Company is expected to be entitled to in exchange for transferring the promised products to the customer. The Company is entitled to the total consideration for the products ordered by customers, net of transaction price adjustments. The Company’s payment terms to customers are generally net 30 days. Payment terms fall within the guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. Assuming all other revenue recognition criteria are met, revenue is recognized when control of the Company’s products transfers to the customer. For sales where the Company’s sales representative hand delivers products directly to the hospital or ASC, control transfers to the customer upon such delivery. For sales where products are shipped, control is transferred either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. The Company recognizes revenue that has been allocated to free leased controllers concurrent with the sale of disposable devices as the lease is cancellable by either party with 30 days’ notice. The amounts allocated to leased controllers are insignificant. As permitted under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The Company accepts product returns at its discretion or if the product is defective as manufactured. Historically, the actual product returns have been insignificant. However, if returns should be become material, the Company will use the expected-value method for estimating returns based on historical data. The Company elected to treat shipping and handling costs as a fulfillment cost and includes them in the cost of goods sold as incurred. In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as revenue. Extended warranty arrangements are recognized ratably over the extended warranty period. For the years ended December 31, 2021 and 2020 warranty revenue was $ 0.1 million and less than $ 0.1 million, and considered insignificant. The Company’s contract liabilities consist of deferred revenue for remaining performance obligations by the Company to the customer after delivery, which is $ 0.1 million as of December 31, 2021. Deferred revenue as of December 31, 2020 was $ 0.2 million, which was recognized as revenue in 2021. Contract costs The Company applies the practical expedient to recognize the incremental costs of obtaining a contract as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year, as the Company does not enter into long-term sales contracts. These incremental costs include sales commissions paid to the Company’s independent sales agents or internal sales representatives. Commissions are recorded as selling expenses. Cost of goods sold The Company manufactures certain products at its facility and purchases other products from third-party manufacturers. Cost of goods sold consists primarily of the third-party manufacturing costs, materials and assembly, direct labor, and charges for excess, obsolete, and non-sellable inventory. Cost of goods sold also includes allocated overhead for indirect labor, depreciation, rent, and information technology. Product warranties The Company generally offers a one-year warranty for its products. The Company provides for the estimated cost of product warranties at the time product revenue is recognized. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. Costs to perform warranty obligations were less than $ 0.1 million for the years ended December 31, 2021 and 2020. Research and development Research and development (R&D) expenses are charged to operations when incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment, depreciation, and utilities. Income taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between the carrying amounts of assets and liabilities used for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company’s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made. The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances, and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50.0% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit). Stock-based compensation We have granted stock-based awards, consisting of stock options restricted stock units to employees and certain non-employee consultants and certain members of our board of directors. The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options and restricted stock units. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. We use the fair value of our common stock to determine the fair value of restricted stock awards . The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. Net loss per share attributable to common stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders, by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrants, convertible notes, common stock subject to repurchase, restricted stock units and common stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security because it participates in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of redeemable convertible preferred stock do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for the years ended December 31, 2021 and 2020, diluted net loss per common share is the same as basic net loss per common share for the periods presented. JOBS Act accounting election The Jumpstart Our Business Startups Act of 2012, (the JOBS Act) permits an “emerging growth company” to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. The Company has elected to use this extended transition period under the JOBS Act. As a result, its financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recent Accounting Pronouncements	3. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurements. The new disclosure requirements include disclosure related to changes in unrealized gains or losses included in other comprehensive income (loss) for recurring Level 3 fair value measurements held at the end of each reporting period and the explicit requirement to disclose the range and weighted-average of significant unobservable inputs used for Level 3 fair value measurements. This ASU removes the requirement to disclose: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. For all entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2018-13 as of January 1, 2020 , and the adoption had no material impact on the Company’s financial statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes. The standard eliminates the need for an organization to analyze whether the following apply in a given period: (1) the exception to the incremental approach for intraperiod tax allocation; (2) the exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (3) the exception in interim periods income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also is designed to improve financial statement preparers’ application of income tax-related guidance and simplify U.S. GAAP for (1) franchise taxes that are partially based on income, (2) transactions with a government that result in a step-up in the tax basis of goodwill, (3) separate financial statements of legal entities that are not subject to tax, (4) enacted changes in tax laws in interim periods and (5) certain income tax accounting for employee stock ownership plans and affordable housing projects. The Company adopted ASU 2019-12 on January 1, 2021 on a prospective basis. The adoption did no t have a material impact on the Company’s financial statements. Recent accounting pronouncements not yet adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). In July 2018, the FASB issued ASU 2018-10 Codification Improvements to Topic 842, Leases, which provides clarification to ASU 2016-02. In March 2019, the FASB issued ASU 2019-01, which provides clarification on implementation issues associated with adopting ASU 2016-02. These ASUs (collectively, the new leasing standard) requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Topic 842 provides a lessee with an option to not account for leases with a term of 12 month or less as leases in the scope of the new standard. Topic 842 supersedes the previous leases standard, Topic 840, Leases. In July 2018, the FASB issued ASU Leases (Topic 842): Targeted Improvements, which allows entities to elect an optional transition practical expedient package where entities may continue to apply the existing lease guidance during the comparative periods and apply the new lease requirements through a cumulative effect adjustment in the period of adoption rather than in the earliest period presented. The new standard is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company adopted this standard on January 1, 2022, using the modified retrospective approach with a cumulative effect adjustment to the accumulated deficit at the beginning of the period of adoption. Topic 842 will impact the Company’s financial statements as the Company has certain operating lease arrangements for which the Company is the lessee. As permitted by the standard, the Company elected the transition practical expedient package, which among other things, allows the carryforward of historical lease classifications. The adoption of this accounting standard update is also expected to impact the Company’s financial statement disclosures. While the Company is finalizing its evaluation of the impact of adopting this accounting standard update on its financial statements and related disclosures, the Company expects to recognize on its balance sheet for associated leases a new right of use (ROU) asset of approximately $ 0.9 million and a new operating lease liability of approximately $ 1.2 million. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, adoption is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For SEC filers that are eligible to be smaller reporting companies and for all other entities, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures. In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically the ASU removes: (1) major separation models required under GAAP and (2) certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contract to qualify for the exception. For public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, this ASU is effective for interim and annual reporting periods beginning after December 15, 2021. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s financial statements and related disclosures.

Revenue

Revenue	12 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenue	4. Revenue Disaggregation of revenue Years Ended December 31, 2021 2020 Minerva ES 46.8 % 55.4 % Genesys HTA 31.6 % 28.5 % Symphion 20.6 % 15.3 % Other 1.0 % 0.9 % 100 % 100 % For the years ended December 31, 2021 and 2020, approximately 99.0 % of the Company’s revenue is subject to point-in-time recognition for single-use (disposable) products and capital equipment sales. Sale of extended warranties on capital equipment represents less than 1.0 % of the Company’s revenue. In addition, more than 98.0 % of the Company’s total revenue is derived from the sale of single-use (disposable) products; therefore, the Company did not include disaggregated revenue data to present the amounts attributed to capital equipment, associated warranties, and miscellaneous revenue separately. Contract balances The Company’s contract balances consist of the following (in thousands): December 31, 2021 2020 Accounts receivable $ 7,292 $ 8,379 Contract liability—current (see "Note 6") $ 206 $ 219

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value measurements	5. Fair value measurements ASC 820, Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820 are described below: Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3—Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis —Financial assets held by the Company measured at fair value on a recurring basis include money market funds which are classified as Level 1 within the fair value hierarchy as the inputs used to measure fair value are quoted prices in active markets for identical assets. Derivative liabilities, contingent consideration liability and redeemable convertible preferred stock warrant liabilities are remeasured at fair value as of each reporting period (See Notes 8 and 11). Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Fair value of assets and liabilities The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2021 and 2020 (in thousands): December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 38,522 $ — $ — $ 38,522 Total financial assets $ 38,522 $ — $ — $ 38,522 Liability: Contingent consideration liability $ — $ — $ 14,094 $ 14,094 Total financial liabilities $ — $ — $ 14,094 $ 14,094 December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 14,638 $ — $ — $ 14,638 Total financial assets $ 14,638 $ — $ — $ 14,638 Liability: Derivative liabilities $ — $ — $ 38,007 $ 38,007 Contingent consideration liability — — 23,667 23,667 Redeemable convertible preferred stock warrant liability — — 42 42 Total financial liabilities $ — $ — $ 61,716 $ 61,716 The redeemable convertible preferred stock warrant liability is classified within Level 3 of the fair value hierarchy because it is valued using the Black-Scholes pricing model, which requires subjective unobservable inputs (See Note 11). Contingent consideration related to the BSC development and revenue milestones is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using a Monte Carlo simulation, and is subject to remeasurement to fair value at each balance sheet date, with any changes in fair value recognized in general and administrative expense, in the statements of operations. The fair value of the mandatory prepayment derivative liability, as a result of a change in control, was calculated using the “with and without” methodology at loan issuance. The “with and without” methodology involves valuing the term loan on an as-is basis and then valuing the term loan without the embedded derivatives. The difference between the value of the term loan with the embedded derivatives and the value without each individual embedded derivative equals the fair value of the embedded derivative. On the subsequent dates, the Company used an income approach to value the term loan derivative liabilities, where the proceeds to the lenders were estimated, adjusted by the opportunit y cost of the lenders for foregoing the debt portion of the instrument. Upon repayment of the Ares Loan in October 2021, the mandatory prepayment derivative liability had no value, because the Company assessed the probability of change in control event to be zero after the IPO (See Note 8). The Company valued the convertible notes derivative liabilities using the income approach, where the proceeds to the convertible noteholders were estimated under different future scenarios, adjusted by the opportunity cost of the convertible noteholders for foregoing the debt portion of the instrument. Each outcome was probability-weighted based on future estimates. The convertible notes derivative liabilities were determined using the following assumptions: December 31, 2020 Expected exit date 6/30/2022 Discount rate 21.0 % Upon the closing of the IPO in October 2021, the 2018, 2019, and 2020 Notes converted into Series D redeemable convertible preferred stock pursuant to automatic conversion feature of the convertible notes (See Note 8). Due to the conversion of the 2018, 2019, and 2020 Notes, the associated derivative liabilities were revalued and extinguished with the change in fair value recorded as other income in the Company’s Statement of Operations. As of December 31, 2020, the estimated fair value of the aggregate outstanding derivative instrument associated with the convertible notes was $ 33.5 million. The change in fair value of the redeemable convertible preferred stock warrant liability, derivative liabilities and contingent consideration liability are summarized below (in thousands) Redeemable Derivative Contingent Beginning fair value, January 1, 2020 $ 75 $ 39,499 $ — Recognition — 6,848 23,842 Change in fair value ( 33 ) ( 8,340 ) ( 175 ) Ending fair value, December 31, 2020 42 38,007 23,667 Beginning fair value, January 1, 2021 42 38,007 23,667 Change in fair value 328 ( 38,007 ) 427 Payment of Development Milestone — — ( 10,000 ) Conversion into common stock warrant ( 370 ) — — Ending fair value, December 31, 2021 $ — $ — $ 14,094

Balance Sheet Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2021
Balance Sheet Components [Abstract]
Balance Sheet Components	6. Balance Sheet Components Cash and cash equivalents The Company’s cash and cash equivalents consist of the following (in thousands): December 31, 2021 2020 Cash $ 2,086 $ 2,721 Cash equivalents: Money market funds 38,522 14,638 Total cash and cash equivalents $ 40,608 $ 17,359 Inventory Inventory consists of the following (in thousands): December 31, 2021 2020 Finished goods $ 9,495 $ 5,068 Component materials 6,187 5,133 Total inventory $ 15,682 $ 10,201 Prepaid expenses and other current assets Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2021 2020 Prepaid expenses $ 1,264 $ 1,794 Prepaid insurance 2,726 122 Other current assets 149 363 Total prepaid expenses and other current assets $ 4,139 $ 2,279 Property and equipment, net Property and equipment, net consist of the following (in thousands): December 31, Useful life (years) 2021 2020 Computers and software 2 $ 730 $ 653 Machinery and equipment 3 997 954 Furniture and fixtures 7 48 48 Tools and dies 2 941 936 Construction in progress — 428 — Equipment under customer usage agreements 3 10,612 7,918 Leasehold improvements Lesser of useful life or lease term 155 155 13,911 10,664 Less: accumulated depreciation and amortization ( 9,317 ) ( 7,784 ) Property and equipment, net $ 4,594 $ 2,880 Depreciation and amortization expense on property and equipment wa s $ 2.4 million and $ 2.0 million, for the years ended December 31, 2021 and 2020, respectively. Of this amo unt, $ 2.1 mill ion and $ 1.6 million, for the years ended December 31, 2021 and 2020, respectively, was related to equipment under customer usage agreements recorded to cost of goods sold. Intangible assets, net Intangible asset, net consist of the following (in thousands): December 31, 2021 Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks $ 3,969 $ ( 992 ) $ 2,977 Developed technology 30,819 ( 5,008 ) 25,811 Customer relationships 13,466 ( 7,294 ) 6,172 Other intangible assets 10 — 10 Total intangible assets $ 48,264 $ ( 13,294 ) $ 34,970 December 31, 2020 Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks $ 3,969 $ ( 382 ) $ 3,587 Developed technology 30,819 ( 1,926 ) 28,893 Customer relationships 13,466 ( 2,805 ) 10,661 Total intangible assets $ 48,254 $ ( 5,113 ) $ 43,141 Amortization expense on intangible assets was $ 8.2 m illion and $ 5.1 million, for the years ended December 31, 2021 and 2020, respectively Future amortization expense of intangible assets as of December 31, 2021 is as follows (in thousands): Year Ending December 31, 2022 $ 8,182 2023 5,376 2024 3,693 2025 3,693 Thereafter 14,016 Total $ 34,960 Accrued compensation Accrued compensation consists of the following (in thousands): December 31, 2021 2020 Accrued vacation $ 1,469 $ 1,184 Accrued bonuses 1,307 831 Accrued commissions 665 828 Other accrued personnel related expenses 77 46 Total accrued compensation $ 3,518 $ 2,889 Accrued liabilities Accrued liabilities consist of the following (in thousands): December 31, 2021 2020 Accrual for litigation $ 7,203 $ 7,203 Accrued professional fees 974 824 Accrued sales and use taxes 657 754 Deferred rent 277 445 Accrual for inventory in transit 119 602 Contract liability 206 219 Others 1,037 157 Total accrued liabilities $ 10,473 $ 10,204

Business Combination

Business Combination	12 Months Ended
	Dec. 31, 2021
Business Combination Description [Abstract]
Business Combination	7. Business Combination On May 11, 2020, the Company completed its acquisition of certain Intrauterine Health products consisting of the Genesys HTA System, Symphion Tissue Removal System, and the Resectr Tissue Resection Device (the acquired IUH products) from BSC. This transaction was accounted for as a business combination. The acquisition included transition services that were provided to Minerva by BSC—these services were to transition the processes necessary to conduct business activities including operating, management, and administrative activities. Also, the Company acquired all supply and consulting contracts relating to the acquired IUH products. The Company accounted for the acquisition of the acquired IUH products under the acquisition method, that requires the assets and liabilities assumed at the date of acquisition to be recorded in the financial statements at their respective fair values at the acquisition date. The excess of fair value of the acquired net assets over the purchase price reflected a bargain purchase gain of $ 0.6 million. The acquired IUH products results of operations are included in the 2020 financial statements from the date of acquisition. The revenue for the acquired IUH products contributed $ 16.9 million, or 44.7 %, of the total revenue from the acquisition date of May 12, 2020 to December 31, 2020. The determination of the estimated fair value of the acquired assets and liabilities requires management to make significant estimates and assumptions. The Company determined the fair value by applying established valuation techniques, based on information that management believed to be relevant to this determination. The Company assessed the fair values of acquired intangible assets, inventory, fixed assets, warranty liability, and purchase consideration including equity-based consideration and contingent consideration. The summary of the purchase consideration is as follows (in thousands, except shares and per share amounts): Description Amount Closing stock consideration — 1,331,411 shares of Series D redeemable convertible preferred stock at $ 2.06 per share $ 2,737 Cash consideration 15,000 Delayed cash consideration 15,000 Development Milestone payment (a) 8,615 Revenue Milestone payments (b) 15,227 Total purchase consideration $ 56,579 The Company estimated the fair value of shares of Series D redeemable convertible preferred stock as $ 2.06 per share, or $ 2.7 million, at the closing date. The Company used the market approach for guideline public companies, guideline transactions, and discounted cash flow methods equally weighted to estimate the total Company’s equity fair value and used the option pricing model to identify the fair value of the newly issued Series D redeemable convertible preferred stock. Contingent consideration consists of the following: (a) Development milestone payment — The Company is required to deliver a development-based milestone payment equal to $ 10.0 million, which was earned when BSC delivered into finished goods inventory the required amount of Symphion controllers, at least 50% of which fully incorporated certain design revisions (the Development Milestone). As of the acquisition date, the Company estimated that there was a 90.0% probability that the Development Milestone would be achieved within 16 months, and the earliest it would be achieved would be the end of March 2021, with May 2021 being the most likely timeframe when the Development Milestone would be achieved. The Company has agreed that this milestone was earned. The Company recorded its estimate of the fair value of the contingent consideration liability for the Development Milestone payment utilizing a discounted cash flow model to determine the present value of the expected value of Development Milestone payment. The Development Milestone was paid in November 2021 upon the completion of the Company's IPO, together with the delayed cash purchase consideration. (b) Revenue milestone payments —The Company is required to make two revenue milestone payments to BSC, which are contingent on the achievement of certain revenue levels from the acquired product lines in 2021 and 2022. The first revenue milestone payment of $ 5.0 million is payable if net revenue from the acquired IUH products is less than or equal to $ 30.0 million in calendar year 2021, and an additional $ 5.0 million if net revenue is greater than $ 30.0 million in calendar year 2021 (the First Revenue Milestone). The First Revenue Milestone payment of $ 5.0 million will be paid within the first three months of 2022. The second revenue milestone payment of $ 5.0 million is payable if net revenue from the acquired IUH products exceeds $ 30.0 million in calendar year 2022 or $ 10.0 million if net revenue is greater than $ 37.0 million in calendar year 2022 (the Second Revenue Milestone) . As of December 31, 2020, based on the revenue forecast of the acquired product lines through 2022, the Company ran a Monte Carlo simulation to estimate risk-neutral future revenue outcomes based on the estimated discount rate applicable to the revenue and the revenue volatility selected based on the guideline public companies. The Company recorded its estimate of the fair value of the contingent consideration liability for revenue milestone payments utilizing the discounted cash flow model to determine the present value of the expected value of the future Revenue Milestone Payments. As of December 31, 2021, the Company recorded its fair value estimate of the contingent consideration liability utilizing the probability of achieving the defined Revenue milestone payments based primarily on updated revenue forecasts. The estimated fair value of the contingent consideration was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC Topic 820, Fair Value Measurement. The fair value measurement for the revenue milestones is directly impacted by the Company’s estimate of future incremental revenue growth of the business. Accordingly, if actual revenue growth is higher or lower than the estimates within the fair value measurement, the Company would record additional charges or benefits, respectively. Each reporting period, the Company will be required to remeasure the fair value of the contingent consideration liability as assumptions change with the change in fair value recorded in general and administrative expenses in the statements of operations. The following table summarizes the allocation of the purchase price based on the estimated fair values of the acquired assets and assumed liabilities as of May 12, 2020 (in thousands): Net assets acquired: Inventory $ 7,846 Other receivable 271 Property and equipment 999 Trade names 3,969 Customer relationships 13,466 Developed technology 30,819 Warranty liability ( 16 ) Deferred tax liability ( 132 ) Negative goodwill ( 643 ) Purchase price $ 56,579 Negative goodwill of $ 0.6 million represents the excess of the fair value of assets acquired and liabilities assumed over the purchase consideration. The Company recorded negative goodwill of $ 0.6 million as a bargain purchase gain in the statements of operations at the acquisition closing date. Before recognizing a gain on bargain purchase, the Company reassessed and concluded that it had identified all of the assets acquired and all of the liabilities assumed. In addition, the Company reviewed the procedures used to measure the amounts to be recognized with respect to identifiable assets acquired and liabilities assumed, as well as the aggregate consideration transferred. The objective of the review was to ensure that the measurements appropriately reflected all available information as of the acquisition date. Based on this review, the Company concluded that the fair value of the consideration transferred in the acquisition of IUH products was less than the fair value of the net identifiable assets acquired, resulting in the $0.6 million gain recognized in connection with the acquisition. The bargain purchase gain resulted primarily from a favorable fair value at the date of acquisition as compared with the Company’s purchase price. The Company identified the following primary factors leading to the bargain purchase gain, which presented the Company with a favorable environment to negotiate pricing and purchase terms, which environment may not have been available had these factors not been present: (1) the Company believes it was the only party desiring to purchase the business; (2) BSC desired to sell the business as evidenced by their reduction in resources and staff dedicated to the business during the 12 months prior to the acquisition; and (3) overall economic environment around the uncertainty of when or if the business would recover from revenue declines resulting from hospital and ASCs restrictions due to COVID-19. Negative goodwill is not taxable and acquired intangible assets are deductible for income tax purposes. Allocating the bargain purchase price to the assets acquired under the residual method results in a deferred tax liability of $ 0.1 million which represents the book to tax differences on other assets and liabilities acquired. Acquired inventory included raw material and finished goods inventory. The fair value of finished goods inventory was measured by using a top-down approach, which starts with a market participant‘s estimated selling price, adjusted for both (1) the costs of the selling effort and (2) an approximately normal profit for the selling effort. The acquisition-date fair value of finished goods inventory was $ 4.3 million. Raw materials inventory was measured at fair value as of the acquisition date applying a bottom-up approach, which uses a market method for valuation if observable market prices are available or a cost approach if they are not. It is assumed in the measurement of a raw material’s fair value that the transaction to sell the raw material occurs in the principal market or, in the absence of a principal market, the most advantageous market. The fair value of raw materials inventory was determined to be its replacement cost. The acquisition-date fair value of raw materials inventory was $ 3.6 million. The fair value of identifiable intangible assets acquired of $ 48.3 million was determined by the Company, with the assistance of a third-party appraiser, primarily using variations of the income valuation approaches, which is based on the present value of the future after-tax cash flows attributable to each identifiable intangible asset. Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not limited to (i) the amount and timing of projected future cash flows (including revenue and expenses), (ii) the discount rate selected to measure the risks inherent in the future cash flows, (iii) the assessment of the asset’s life cycle, and (iv) the contributory asset charges. The components of identifiable intangible assets acquired were as follows (in thousands) : Useful lives (4) Value as of Trademarks (1) 6.5 $ 3,969 Developed technology (2) 10 30,819 Customer relationships (3) 3 13,466 Total identifiable intangible assets acquired $ 48,254 (1) The relief from royalty method of the income approach was used to estimate the fair value of the trademarks. (2) Developing technology was valued using the excess earnings method (3) Customer relationship assets represent the expected profits to be generated from the customer contracts, incorporating estimated customer retention rates. (4) The estimated useful lives were determined based on the future economic benefit expected to be received from the assets . Transaction costs associated with the acquisition were $ 1.0 million during the year ended December 31, 2020 and were expensed as incurred in general and administrative expenses in the statements of operations. In May and September 2021, the Company amended the Asset Purchase Agreement with BSC to modify the delayed consideration payment and contingent consideration due as follows: (1) the timing of the delayed $15.0 million payment was deferred from May 11, 2021 to the earlier of 15 days post-IPO or November 1, 2021; (2) the timing of the $10.0 million Development Milestone payment was changed to 15 days post-IPO or, if the IPO has not been completed by November 1, 2021, upon the earlier of the closing of the Company’s first financing after November 1, 2021 or the date that the first Revenue Milestone Payment is due and it was agreed that the Development Milestone payment was achieved; and (3) the first Revenue Milestone Payment was modified from either $5.0 million if net revenue from the acquired IUH products exceeds $26.0 million in 2021 or $10.0 million if net revenue exceeds $30.0 million in 2021, to either $5.0 million if revenue from acquired IUH products in 2021 is less than $30.0 million or $10.0 million if more than $30.0 million in 2021. As a result, fair value of contingent consideration changed by $ 0.4 million wh ich was recognized in general and administrative expense in the statement of operations for the year ended December 31, 2021. In November 2021, the Company paid BSC $ 15.0 million and $ 10.0 million for the delayed cash purchase consideration and Development Milestone payment, respectively. Pro-forma financial information (unaudited) The unaudited pro forma revenue and net loss for the year ended December 31, 2020 assuming the acquisition had occurred on January 1, 2019 was $ 44.7 million and $ 17.3 million respectively. The unaudited pro forma information was determined based on the historical GAAP results of the Company and abbreviated financial information of IUH products acquired from BSC. The unaudited pro forma results are not necessarily indicative of what the Company’s results of operations would have been if the acquisition was completed on January 1, 2019, nor do they give effect to synergies, cost savings, fair market value adjustments, and other changes expected to result from the acquisition. Accordingly, the pro forma financial results do not purport to be indicative of results of operations as of the date hereof, for any period ended on the date hereof, or for any other future date or period. The unaudited pro forma net loss for year ended December 31, 2020 includes pro forma adjustments of $ 3.1 million relating to the adjustment for the amortization of the intangible assets from January 1, 2020 through May 12, 2020 and the reduction of $ 1.0 million in transaction costs, which were assumed to have been incurred at the inception of the acquisition .

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	8. Debt Ares term loan On December 30, 2019, the Company entered into a Credit Agreement (the Ares Agreement) with Ares Capital Corporation and Ares Direct Finance I LP (collectively, Ares) to raise up to $ 40.0 million in debt financing (the Ares Loan) consisting of $ 30.0 million advanced at the closing of the agreement (Tranche A), with the option to draw up to an additional $ 10.0 million (Tranche B) on or before December 31, 2020 , which was conditioned upon achieving a minimum of $ 30.0 million in net revenues in the prior 12-month period. The Ares Loan has a three-year term maturing on December 31, 2022 , which includes eight quarters of interest-only payments followed by four quarters of equal payments of principal and interest. The interest-only period could be extended to ten quarters if the Company satisfied certain amortization period extension conditions prior to December 31, 2021. In May 2020, the Company satisfied one of the amortization period extension conditions and the interest-only period was extended to ten quarters. Borrowings under the Ares Agreement, including the Ares Loan, bear interest at either the ABR plus 8.5% per annum or the Eurodollar Rate plus 9.5% per annum, as applicable. The ABR equals the greatest of (a) 3.0%, (b) the prime rate, (c) the federal funds rate plus 0.5% and (d) the three-month Eurodollar Rate plus 1.0%. The Eurodollar Rate equals the greater of (a) 2.0% and (b) the rate per annum appearing on Bloomberg Professional Service Page BBAM1 offered rate for deposits in U.S. dollars at approximately two business days prior to the first day of such interest period for a three (3) month term; multiplied by the Statutory Reserve Rate. The Statutory Reserve Rate is based on a fraction, the numerator of which is the number one and the denominator of which is the number one minus the applicable reserve percentage for that day. Payments of interest under Ares Loan are to be made quarterly commencing on March 31, 2020. Through December 31, 2021, the Company has the option to pay all accrued interest in cash or by paying up to 50.0 % of accrued interest in kind (PIK interest) by increasing the principal amount of Ares L oan. On each payment date through June 30, 2021, the Company elected the PIK option, issuing PIK notes totaling $ 2.9 million. For three months ended September 30, 2021, the Company did not use PIK option and paid all interest in cash. As of October 8, 2021 (repayment date) the Ares Loan had an annual effective interest rate of 24.9 % per annum. As of December 31, 2020 the annual effective interest rate of was 22.7 % per annum. The Ares Loan is collateralized by substantially all of the Company’s assets. The Company may prepay the loan, subject to prepayment premium equal to 30.0 % of the principal amount being prepaid less all interest payments and fees paid in cash on or prior to the date of such prepayment, provided that in no event shall the prepayment premium be less than zero. The Ares Loan includes a fee upon repayment of the loan ranging from 4.0 % to 10.0 % of the aggregate principal amount being prepaid or repaid including all PIK notes added to the principal amount. The Ares Agreement includes customary restrictive covenants, financial covenants, events of default and other customary terms and conditions. The financial covenants in the Ares Agreement require the Company to have revenue for the four consecutive fiscal quarters period ending on March 31, 2020, and the last day of each June, September, December and March thereafter, off not less than the minimum revenue amount specified in the Ares Agreement and maintain a minimum cash and cash equivalents balance of $ 5.0 million at any time. In January 2021, the Company entered into a waiver and amendment agreement to the Ares Agreement to receive a waiver for certain reporting covenants for which the Company was not in compliance. Additionally, the amendment extended the Tranche B availability date to June 30, 2021. The amendment was accounted for as a debt modification and no gain or loss was recognized. In March 2021, the Company entered into a second amendment to the Ares Agreement to extend the compliance period for certain reporting covenants. The amendment was accounted for as a debt modification and no gain or loss was recognized. In July 2021, the Company amended the terms of the Ares Agreement to waive a default in connection with the Company’s failure to satisfy a covenant relating to delivery of financial statements and modify that financial reporting covenant. The amendment also served to modify the fee due to Ares upon repayment of the loan from a variable amount based on equity value of the Company to a fixed exit fee of 6.25 % of the principal amount of the Loans funded under the Ares Agreement. In addition, the timing for delivery of the Company’s annual audited financial statements was amended to 210 days from the end of the fiscal year for the year ended December 31, 2020. The amendment was accounted for as a debt modification and no gain or loss was recognized. The Company may be required to make mandatory prepayments of the Ares Loan upon the occurrence of specified prepayment trigger events, including the occurrence of any event of default or the occurrence of a change in control event. Upon the prepayment of all or any of the outstanding principal balance, the Company shall pay, in addition to such prepayment, the prepayment premium noted above. As Ares may exercise the option to require prepayment by the Company, the prepayment premium is considered to be an embedded derivative which is required to be bifurcated from its host contract and accounted for as a separate financial instrument. The mandatory prepayment derivative liability had a fair value of $ 4.3 million upon entering into the Ares Agreement, which was accounted for as a debt discount. On October 8, 2021, the Company repaid its entire obligation under the Ares Loan amounting to $ 35.5 million, including principal of $ 32.8 million, accrued interest of $ 0.1 million and fees of $ 2.6 million, using the proceeds from CIBC Term Loan (described below). The repayment of the obligation under the term loan agreement with ARES was accounted as a debt extinguishment and the Company recorded a loss on a debt extinguishment of $ 4.4 million accordingly in the statements of operations. The Ares Loan consists of the following (in thousands): December 31, 2020 Term loan principal $ 31,878 Less: debt issuance cost and debt discount ( 4,120 ) Add: exit fee 312 Term loan $ 28,070 The Co mpany paid $ 1.4 million in fees to the lender and third parties which is reflected as a discount on the Ares Loan and is being accreted over the life of the term loan using the effective interest method. During the years ended December 31, 2021 and 2020, the Company recorded interest expense of $ 4.9 million and $ 5.6 million, respectively, which includes interest expense related to the accretion of debt discount, debt issuance costs and exit fee of the Ares Loan of $ 2.0 million and $ 1.9 million, respectively . As of December 31, 2021 and 2020, the estimated fair value of the aggregate outstanding derivative instrument associated with the Ares Loan was zero and $ 4.5 million, respectively. Paycheck Protection Program In April 2020, the Company received $ 3.0 million from a Federal Small Business Administration (SBA) loan under the Paycheck Protection Program (the PPP Loan). The PPP Loan bore interest at 1.0 % per year on the outstanding principal amount and was scheduled to mature 24 months from the date of the note. No payments were due for initial six-month period of the PPP Loan. Afterwards, payments of principal and interest were due over the following 18 months. In June 2021, the Company received formal notification from the SBA that the Company’s PPP Loan and interest had been formally forgiven in the principal amount of $ 3.0 million, plus interest of less than $ 0.1 million. As a result, the Company recognized a $ 3.0 million gain on forgiveness of PPP loan in the statement of operations for the year ended December 31, 2021. CIBC term loan On October 8, 2021, the Company entered into a Loan and Security Agreement (the CIBC Agreement) with Canadian Imperial Bank of Commerce (CIBC), which provides for a senior secured term loan in an aggregate principal amount of $ 40.0 million (the CIBC Loan), the full amount of which was funded at the closing of the CIBC Agreement. Most of the proceeds of the CIBC Loan were used to repay the Company’s entire obligation under its existing loan agreement with Ares, including the principal, interest, prepayment premium and fees, in a total amount of $ 35.5 million. The CIBC Loan provides for 24 months of interest-only payments followed by 36 equal monthly payments of principal, plus accrued and unpaid interest, with the final obligations due and payable in full on October 8, 2026. The CIBC Loan accrues interest at a floating rate equal to 2.5 % above the prime rate, an d the interest is payable monthly in arrears. As of December 31, 2021, the CIBC Loan had an annual effective interest rate of 6.72 % per annum. Obligations under the CIBC Agreement are secured by substantially all of the Company’s assets. The CIBC Agreement contains customary affirmative and n egative covenants, including, among other requirements, financial statement reporting requirements, limitations on the incurrence of certain indebtedness and liens, limitations on the disposition of assets, restrictions on certain transactions with affiliates, limitations on dividends and stock repurchases and a material adverse change event of default. The CIBC Agreement also contains financial covenants that require the Company to maintain minimum revenue and minimum cash thresholds. The Company may prepay the CIBC Loan in whole or in part, subject to a prepayment premium ranging from 0.0 % to 3.0 % of the principal amount of the CIBC Loan that is prepaid, depending on the timing of the prepayment. In connection with issuance of the Loan, the Company entered into a Success Fee Agreement with CIBC on the same date. In the event of a sale or other disposition by the Company of all or substantially all of its assets, a merger or consolidation, or an initial public offering before the expiration of the Success Fee Agreement on October 8, 2026, the Company is required to pay to CIBC the Success Fee of up to $ 0.4 million. On October 26, 2021, in connection with the IPO, the Success Fee derivative liability was settled upon the Company paying $ 0.4 million Success Fee to CIBC pursuant to the Success Fee Agreement. The CIBC Agreement contains customary events of default subject to customary cure periods for certain defaults that include, among others, non-payment defaults, inaccuracy of representations and warranties, covenant defaults, cross-defaults to certain other material indebtedness, bankruptcy, and insolvency events with respect to the Company, and material judgements. Upon the occurrence and during the continuance of an event of default, CIBC may a ccelerate the Company’s obligations under the CIBC Agreement, increase the applicable interest rate by 5.0 % and exercise other remedies provide d for under the CIBC Agreement and applicable law. The CIBC Loan consists of the following (in thousands): December 31, 2021 Term loan principal $ 40,000 Less: Debt issuance cost and debt discount ( 915 ) Accrued interest 189 Term loan $ 39,274 The Company paid $ 1.0 million in fees to CIBC and third parties which is reflected as a debt discount and debt issuance costs, respectively, and are being accreted over the life of the term loan using the effective interest method. During the year ended December 31, 2021 the Company recorded interest expense of $ 0.6 million, which includes interest expense related to accretion of debt discount and debt issuance costs of the CIBC Loan of $ 0.1 million. Convertible notes In March and December 2018, the Company entered into Second Lien Loan and Security Agreements (the 2018 Note Agreements) with certain investors, for up to $ 20.0 million and $ 10.0 million in convertible notes, respectively. The convertible notes under these 2018 Note Agreements are collateralized by assets, including cash and cash equivalents, accounts receivable, and property and equipment. Under the 2018 Note Agreements, the investors agreed to make one or more convertible notes (the 2018 Notes) to the Company during the period beginning in March and December 2018, respectively, and ending on the one-year anniversary of the 2018 Note Agreements, the maturity date. In May and November 2019, the Company entered into additional Second Lien Loan and Security Agreements (the 2019 Note Agreements) with certain investors, each for up to $ 10.5 million in convertible notes. With the exception of the issuance date of offering and maturity date, all remaining contractual terms of the 2019 Note Agreement are similar to the 2018 Note Agreements. Under the 2019 Note Agreements, the investors agreed to make one or more convertible notes to the Company during the period beginning in May and November 2019 (the 2019 Notes) and ending on the one-year anniversary of the 2019 Note Agreement, the maturity date. In December 2019, the Company and the investors entered into an amendment to the 2018 Notes and 2019 Notes (the Amendment), which extended the maturity of the 2018 Notes and 2019 Notes to June 2023 . Moreover, the 2018 Notes and 2019 Notes were subordinated to the term loan with Ares Capital Corporation, and collateralized by assets, including cash and cash equivalents, accounts receivable, and property and equipment. In May 2020, the Company entered into another Second Lien Loan and Security Agreement (the 2020 Note Agreement) with certain investors, for up to $ 30.0 million in convertible notes. The convertible notes under the 2020 Note Agreement are subordinated to the term loan with Ares Capital Corporation and are also collateralized by assets, including cash and cash equivalents, accounts receivable and property and equipment. Under the 2020 Note Agreement, the investors agreed to make one or more convertible notes to the Company during the period beginning in May 2020 (the 2020 Notes), and ending on June 30, 2023 , the maturity date. On September 3, 2021, the Company amended the 2018 Note Agreements, 2019 Note Agreements, and 2020 Note Agreement to modify the maturity dates to December 31, 2026 and to add automatic conversion of these convertible notes’ outstanding principal and accrued interest into shares of common stock if either (i) the offering price per share of our IPO is greater than $ 5.61 and the aggregate gross proceeds to the Company from the IPO are greater than $ 50.0 million or (ii) the Company receives a written request from the holders of at least 66 2/3% of the redeemable convertible preferred stock to convert all outstanding redeemable convertible preferred stock to common stock. The Amendment was accounted for as a debt extinguishment, and the Company recognized a $ 16.9 million extinguishment loss in other income (expense), net in the statement of operations for the year ended December 31, 2021. The 2018 Notes, 2019 Notes, and 2020 Notes (collectively, the Convertible Notes) accrue interest at a fixed rate of 8.0 % per annum. Interest accrues until the convertible notes are converted to equity shares or paid in full. Each convertible note is evidenced by a separate Secured Convertible Note. The Company borrowed $ 29.2 million in 2018, $ 21.0 million in 2019, and $ 15.0 million in 2020 under the Second Lien Loan and Security Agreements with investors. At October 21, 2021 (prior to the closing of the IPO date), the Company retained the ability to draw up to an additional $ 15.0 million under the 2020 Note Agreement in order to satisfy certain deferred payment obligations due to BSC. Immediately prior to the closing of the IPO, $ 79.2 million in aggregate outstanding p rincipal and accrued interest of the convertible notes converted into 7,006,228 shares of redeemable convertible preferred stock at a conversion price of $ 11.31 per share. Upon conversion the carrying value of the debt, including the $ 79.2 million in aggregate outstanding principal and accrued interest and $ 10.1 million in unamortized premium, was reclassified to additional paid-in capital. Also immediately prior to the IPO closing, all outstanding shares of the Company's redeemable convertible preferred stock (including th ose issued upon conversion of the convertible notes) converted into 19,404,066 shares of common stock which resulted in the reclassification of the carrying value of the preferred stock to common stock and additional paid-in capital. The convertible notes contained embedded features – a qualified financing put, non-qualified financing put, and change of control put features that were bifurcated and accounted as derivative liabilities and recorded as debt discount. Debt discount is reported as a direct deduction to the carrying amount of the convertible notes and amortized using the effective interest rate over the life of the convertible notes as interest expense. The embedded derivative features are recorded at fair value upon entering into the note purchase agreements and are subject to remeasurement to fair value at each balance sheet date, with any changes in fair values recognized in the statements of operations. During the years ended December 31, 2021 and 2020, the Company reported amortization of debt premium and discount of $ 1.3 million and $ 1.4 million, respectively. The convertible notes consist of the following (in thousands): December 31, 2020 Principal $ 69,245 Less: debt issuance costs ( 38 ) Less: debt discount ( 8,145 ) Accrued interest 5,134 Convertible notes $ 66,196 During the year ended December 31, 2021, the Company recorded interest expense of $ 6.3 million on the 2018, 2019 and 2020 Notes. During the year ended December 31, 2021, the Convertible Notes had an annual effective interest rate ranging from 5.0 % to 6.2 % per year. During the year ended December 31, 2020, the Company recorded interest expense of $ 6.5 million on the 2018, 2019 and 2020 Notes. During the year ended December 31, 2020, the Convertible Notes had an annual effective interest rate ranging from 9.0 % to 31.0 % per year. As of December 31, 2020, the Convertible Notes had accrued interest of $ 5.1 million. Contractual maturities of financing obligations As of December 31, 2021, the aggregate future payments under the CIBC Loan (including interest payments) are as follows (in thousands): 2022 $ 2,300 2023 4,457 2024 14,807 2025 14,060 2026 12,229 Total 47,853 Less: unamortized debt discounts and issuance costs ( 915 ) Less: interest ( 7,664 ) Term loan $ 39,274

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Operating lease The Company's corporate headquarters, research and development facilities, and manufacturing and distribution centers are located in Santa Clara, CA and are subject to a non-cancellable operating lease that terminates in 2023 . The future minimum rental obligations required under non-cancellable lease on December 31, 2021 are as follows (in thousands): 2022 $ 846 2023 358 Total minimum lease payments $ 1,204 Total rent expense was approxim ately $ 0.7 million and $ 1.1 million, for the years ended December 31, 2021 and 2020, respectiv ely. Indemnification The Company enters into indemnification provisions under its agreements with other companies in the ordinary course of business, including business partners and contractors. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party as a result of the Company’s activities. The terms of these indemnification agreements are generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. The Company maintains commercial general liability insurance and products liability insurance to offset certain of its potential liabilities under these indemnification provisions. Litigation The Company regularly evaluates its exposure to threatened or pending litigation and other business contingencies. Because of the uncertainties related to the amount of loss from litigation and other business contingencies, the recording of losses relating to such exposures requires significant judgment about the potential range of outcomes. As additional information about current or future litigation or other contingencies becomes available, the Company will assess whether such information warrants the recording of additional expense. In November 2015, Hologic, Inc. and Cytyc Surgical Products, LLC (collectively Hologic) filed a complaint against the Company alleging infringement of four patents (two of the four asserted patents, one of which was invalidated by the Company, were dropped pre-trial by Hologic). Before trial, the court determined on summary judgment that the Company infringed the two remaining patents. At trial, Hologic sought approximately $ 16 M in damages. On July 27, 2018, a Delaware jury returned a verdict finding the Company did not willfully infringe and awarded Hologic $ 4.8 million in damages for lost profits and for royalties not included in the lost profits. Based on the result of the trial in July 2018 with Hologic, the Company recorded an accrual for potential legal losses of $ 4.8 million as of December 31, 2017 with a corresponding expense within general and administrative expenses. Post-trial, the Court of Appeals for the Federal Circuit (Federal Circuit) affirmed the Patent Office’s determination that one of Hologic’s two remaining patents was also invalid, leaving one patent in dispute. After the completion of post-trial motions and after the final orders from the court, in July 2019, the Company filed a notice of its intent to appeal to the Federal Circuit. At the time the appeal was filed, the updated damages calculation totaled $ 7.1 million and the related cash balance was restricted from withdrawal. A surety bond was generated and filed along with the appeal documents and included in restricted cash in the balance sheet. The additional damages were accrued for as of December 31, 2018. On April 22, 2020, the Federal Circuit affirmed the verdict of the $ 7.1 million in total damages. In September 2020 the Company filed a petition for certiorari with the U.S. Supreme Court appealing from the Federal Circuit’s affirmance. The Company’s petition was granted, was heard in late April 2021, and the Supreme Court issued its Opinion in June 2021 remanding back to the Federal Circuit for further consideration (see below). On remand, the Federal Circuit heard oral arguments on January 27, 2022. No opinion has been issued. On July 8, 2020, Hologic sued the Company for willful infringement of the same remaining Hologic patent in the U.S. District Court for the District of Delaware, alleging that the Company’s new ES Handpiece infringed the now expired patent (the one remaining patent in question expired in November of 2018 and therefore only past damages for approximately five months of sales remains at issue in the case). The Company has answered, denying infringement and willfulness and alleges that the patent was invalid prior to expiry. Due to COVID-19, the case was stayed twice for 60 days. On January 22, 2021, the Company filed a motion to stay this case until such time as all appeals of the first case have run their course (see above), and that motion was granted. On June 29, 2021, the U.S. Supreme Court vacated and remanded the Federal Circuit’s decision that the Company cannot challenge the validity of the one remaining Hologic patent due to assignor estoppel. As noted above, a decision from the Federal Circuit following the January 27, 2022 oral argument is expected to be issued in the future. In April 2017, the Company sued Hologic for willful infringement of a Company patent in the U.S. District Court for the Northern District of California. Hologic has answered, denying infringement and willfulness and alleging invalidity of the patent. The Company sought a preliminary injunction and that motion was denied. This matter was transferred to the U.S. District Court for the District of Delaware, where it has been assigned to the same judge presiding over the Hologic complaints. Due to COVID-19, the July 2020 trial date was delayed. On July 20, 2021, the district court granted Hologic’s Daubert motion excluding certain expert opinions regarding infringement. On July 23, 2021, the district court found on summary judgment that the Company’s patent is invalid, dismissed the case and entered judgment. On August 24, 2021, the Company filed its notice of appeal and has appealed to the Federal Circuit. The Company’s opening brief was filed on December 9, 2021. Hologic’s response brief was filed on March 4, 2022, The Company's response is due on March 25, 2022 and no date for oral argument has been set yet.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes All losses before income ta xes were generated in the United States. The Company recorded a deferred income tax benefit of $ 0.1 million in the year ended December 31, 2020 and a current income tax expense of less than $ 0.1 million in the year ended December 31, 2021. The reconciliation between the federal statutory rate and the Company’s effective tax rate is summarized below: Years Ended December 31, 2021 2020 Federal statutory rate 21.00 % 21.00 % State blended rate 4.99 % 3.34 % Stock-based compensation ( 3.61 %) ( 0.77 %) Gain (loss) on debt extinguishment ( 8.53 %) —% Other permanent items ( 0.47 %) ( 0.13 %) Change in valuation allowance ( 62.41 %) ( 25.48 %) Convertible debt embedded derivative 44.95 % 1.94 % Other 4.02 % 0.82 % Effective tax rate ( 0.06 %) 0.72 % The tax effects of temporary differences and carryforwards of the deferred tax assets and liabilities are presented below (in thousands): December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 50,494 $ 44,568 Depreciation and amortization 4,656 3,375 Accruals and reserves 3,577 2,666 Interest expense limitation carryforward 2,229 — Research and development credits 2,250 2,197 Gross deferred tax assets $ 63,206 $ 52,806 Less: valuation allowance ( 63,206 ) ( 49,817 ) Net deferred tax assets $ — $ 2,989 Deferred tax liability: Convertible debt embedded derivative — ( 2,989 ) Total $ — $ — The valuation allowance increased by $ 13.4 million and $ 4.7 million for the years ended December 31, 2021 and December 31, 2020, respectively. Realization of deferred tax assets is dependent upon future earnings, if any, the timing of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. As of December 31, 2021, the Company had federal and state net operating loss carry forwards of approximately $ 188.1 million and $ 165.5 million, respectively, available to reduce future taxable income, if any. The net operating loss carry forwards will expire beginning in 2028 for both federal and California income tax purposes. Federal net operating losses generated beginning in 2018 are carried forward indefinitely. As of December 31, 2021, the Company had federal and state research credit carry forwards of $ 1.5 million and $ 1.5 million available to reduce future taxable income, if any, for both federal and California state income tax purposes, respectively. Federal tax credits begin to expire in 2029 and California credits carryforward indefinitely. Utilization of the net operating loss carry forwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended and similar state provisions. A Section 382 "ownership change" generally occurs if one or more stockholders or groups of stockholders, who own at least 5 % of the Company's stock, increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. The Company performed the analysis in 2021 and determined that it has experienced an ownership change in February 2010 as a result of stock transfers and the issuance of preferred stock. This change in ownership does not significantly impact the Company’s federal and state net operating loss carryforwards and research and development credit carryovers as of December 31, 2021 pursuant to Section 382 and Section 383 of the Internal Revenue Code and similar provisions under state law. The Company follows the provisions of FASB ASC 740-10, Accounting for Uncertainty in Income Taxes. ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. The following table reflects changes in the unrecognized tax benefits since January 1, 2020 (in thousands): December 31, 2021 2020 Gross amount of unrecognized tax benefits as of the beginning of the period $ 447 $ 431 Increases related to current year tax provisions 18 16 Gross amount of unrecognized tax benefits as of the end of the period $ 465 $ 447 As of December 31, 2021, the Company has unrecognized tax benefits of approximately $ 0.5 million. It is unlikely that the amount of liability for unrecognized tax benefits will significantly change over the next 12 months. It is the Company's policy to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary. Due to the Company’s full valuation allowance, the unrecognized tax benefits would not materially impact the Company’s effective tax rate when recognized. The Company's tax years 2008 through 2021 will remain open for examination by the federal and state authorities for three and four years , respectively, from the date of utilization of any net operating losses and tax credits.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock Warrants and Common Stock Warrants	12 Months Ended
	Dec. 31, 2021
Redeemable Convertible Preferred Stock Warrants and Common Stock Warrants [Abstract]
Redeemable Convertible Preferred Stock Warrants and Common Stock Warrants	11. Redeemable Convertible Preferred Stock Warrants and Common Stock Warrants Warrants for Series D redeemable convertible preferred stock In May 2017, in connection with the term loan agreement, the Company issued warrants to purchase a total of 33,964 shares of Series D redeemable convertible preferred stock. All warrants were immediately exercisable and expire 10 years from issuance. In July 2019, in connection with an amendment to the term loan, the Company issued warrants to purchase a total of 43,878 shares of Series D redeemable convertible preferred stock at an exercise price equal to the original purchase price of the Series D redeemable convertible preferred stock (subject to certain adjustments). All warrants were immediately exercisable and expire 10 years from issuance. As of their issuance date in July 2019, the Company estimated the fair value of Series D warrants to be $ 73,406 using the Black-Scholes option-pricing model. As of December 31, 2020, warrants to purchase 77,842 shares of Series D redeemable convertible preferred stock were outstanding. All warrants for Series D redeemable convertible preferred stock were exercisable at a price of $ 11.31 per share as of December 31, 2020. On October 21, 2021 the Company estimated the fair value of Series D warrants upon the closing of the IPO, which was $ 0.4 million . According to Series D Warrants agreements upon the closing of IPO the Series D warrants were to be automatically converted into common stock warrants. Upon the closing of the IPO, the redeemable convertible preferred stock warrant liability was reclassified to additional paid-in capital as the common stock warrants meet all criteria for equity classification. The redeemable convertible preferred stock warrant liability was valued using the following assumptions under the Black-Scholes option-pricing model: October 22, 2021 December 31, 2020 Expected dividends 0 % 0 % Expected volatility 51.4 % - 54.7 % 48.2 % - 52.4 % Risk-free interest rate 1.3 % - 1.5 % 0.6 % - 0.8 % Expected warrant life 5.5 - 7.7 years 6.4 - 8.6 years Common stock warrants As of December 31, 2021, the Company`s outstanding warrants to purchase shares of common stock, consisted of the following: Issuance Date Number of Shares of Common Stock Issuable Exercise Price Classification Expiration Date May 9, 2017 33,964 $ 11.31 Equity May 8, 2027 July 19, 2019 43,878 $ 11.31 Equity July 18, 2029 77,842

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2021
Temporary Equity Disclosure [Abstract]
Redeemable Convertible Preferred Stock	12. Redeemable Convertible Preferred Stock Under the Company’s Amended and Restated Certificate of Incorporation, the Company is authorized to issue up to 5,000,000 shares of $ 0.001 par value preferred stock. Upon the closing of the IPO in October 2021, all outstanding shares of the convertible preferred stock converted into 12,397,838 shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital. There was no issued and outstanding redeemable convertible preferred stock as of December 31, 2021. As of December 31, 2020, redeemable convertible preferred stock consists of the following (in thousands, except per share and share amounts): Series Number of Shares Authorized Number of Shares Issued and Outstanding Carrying Value Liquidation Preference per Share Liquidation Value Series A 2,725,000 450,692 $ 2,725 $ 6.05 $ 2,725 Series B 4,083,542 675,397 5,845 8.89 6,003 Series C 13,995,537 2,223,888 24,980 11.31 25,144 Series D 100,928,318 9,047,861 89,705 11.31 102,296 Total 121,732,397 12,397,838 $ 123,255 $ 136,168 The rights, preferences and privileges of the redeemable convertible preferred stockholders are as follows: Dividends —The holders of redeemable convertible preferred stock are entitled to receive noncumulative dividends, when and if declared by the Board of Directors, out of any assets legally available, prior to and in preference to any declaration or payment of dividends on the common stock of the Company. Dividend rates, on a per annum basis, for Series A, Series B, Series C, and Series D redeemable convertible preferred stock are $ 0.4837 , $ 0.7110 , $ 0.9045 , and $ 0.9045 per share, respectively (adjusted to reflect subsequent stock dividends, stock splits, and recapitalization). After payment of such dividends, any additional dividends (other than dividends on Common Stock payable solely in Common Stock) shall be distributed to the holders of all redeemable convertible preferred stock and common stock on a pro rata basis in proportion to the number of common stock held by each stockholder as if the preferred stock had been converted at the effective conversion rate. No dividends have been declared to date. Voting Rights —The holders of redeemable convertible preferred stock are entitled to vote on all matters on which the common stock holders are entitled to vote. Holders of redeemable convertible preferred and common stock vote together as a single class. Each holder of redeemable convertible preferred stock is entitled to the number of votes equal to the number of common stock shares into which the shares held by such holder are convertible. As of December 31, 2020, the Board of Directors was comprised of ten members. The holders of Series A, B and C redeemable convertible preferred stock, voting as a separate classes, respectively, shall be each be entitled to elect one member of the Company’s Board of Directors. The holders of Series D redeemable convertible preferred stock, voting as a separate class, shall be entitled to elect two members of the Company’s Board of Directors. The holders of Common Stock, voting as a separate class, shall be entitled to elect three members of the Company’s Board of Directors. All remaining members of the Board of Directors shall be elected by the holders of Common Stock and redeemable convertible preferred stock, voting as a single class and on an as-converted basis. Liquidation —In the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, the holders of the redeemable convertible preferred stock are entitled to receive an amount per share prior and in preference to any distribution of any of the assets of the Company to the holders of common stock. The amount to be distributed will be calculated as (1) the liquidation preference ($ 6.05 per share for Series A redeemable convertible preferred stock, $ 8.89 per share for Series B redeemable convertible preferred stock, $ 11.31 per share for Series C redeemable convertible preferred stock and $ 11.31 per share for Series D redeemable convertible preferred stock) plus (2) all declared but unpaid dividends on the redeemable convertible preferred stock. If, upon the winding up of the Company, the assets legally available for distribution are insufficient to cover the amounts owed to the holders of redeemable convertible preferred stock, the assets shall be distributed with equal priority and pro rata among the holders of redeemable convertible preferred stock in proportion to the full amounts that they would have received had funds been sufficient. After the payment of the liquidation preference, all remaining assets available for distribution, if any, shall be distributed among the holders of common stock. A liquidation, dissolution or winding up of the Company shall be deemed to be occasioned by, or include, (A) the acquisition of the Company by another entity by means of any transaction or series of related transactions to which the Company is party (including, without limitation, any stock acquisition, reorganization, merger or consolidation) other than a transaction or series of transactions in which the holders of the voting securities of the Company outstanding immediately before such transaction continue to retain in substantially the same proportions as existed prior to such transactions or related transactions (either by such voting securities remaining outstanding or by such voting securities being converted into voting securities of the surviving entity), as a result of shares in the Company held by such holders before such transaction, at least 50.0% of the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such transaction or series of transactions, or (B) a sale, lease or other conveyance of all or substantially all of the assets of the Company. Conversion —Each share of redeemable convertible preferred stock shall be convertible, at the option of the holder at any time after the date of issuance into the number of fully paid and non-assessable shares of common stock as determined by dividing the original issue price per share of each series of redeemable convertible preferred stock by the conversion price per share in effect for the shares of each series of redeemable convertible preferred stock at the time of conversion. The original conversion price per share of Series A, Series B, Series C, and Series D redeemable convertible preferred stock shall be the original issue price, subject to adjustment, as described in the Company’s Amended and Restated Certificate of Incorporation. Each share of redeemable convertible preferred stock shall automatically be converted into fully-paid, non-assessable shares of common stock at the then effective conversion rate at the time in effect for such share immediately upon the earlier of (i) the Company’s sale of its common stock in a firm commitment underwritten public offering (public offering price of which is not less than $ 5.61 per share as adjusted for recapitalization, stock combinations, stock dividends, stock splits and the like) and which results in aggregate cash proceeds to the Company of at least $ 50,000,000 (before underwriting discounts, commissions, and fees), or (ii) upon the receipt by the Company of a written request for such conversion from the holders of at least 66 2/3 % of the redeemable convertible preferred stock then outstanding voting as a single class and on an as-converted basis, or, if later, the effective date for conversion specified in such requests. Redemption —Convertible preferred stock is not redeemable. The redeemable convertible preferred stock is recorded within mezzanine equity because, while it is not mandatorily redeemable, it will become redeemable at the option of the holders upon the occurrence of certain deemed liquidation events that are considered not solely within the Company’s control.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders' Equity (Deficit)	13. Stockholders’ Equity (Deficit) Common stock The Amended and Restated Certificate of Incorporation authorizes the Company to issue up to 144,406,928 shares of common stock. In connection with the completion the IPO in October 2021, the Company's certificate of incorporation was amended and restated to provide for 100,000,000 authorized shares of common stock with a par value of $ 0.001 per share. Shares reserved for future issuance The Company has reserved shares of common stock for future issuances as follows: December, 31 2021 2020 Series A redeemable convertible preferred stock outstanding — 450,692 Series B redeemable convertible preferred stock outstanding — 675,397 Series C redeemable convertible preferred stock outstanding — 2,223,888 Series D redeemable convertible preferred stock outstanding — 9,047,861 Warrants to purchase Series D redeemable convertible preferred stock — 77,842 Warrants to purchase common stock 77,842 — Common stock options issued and outstanding 2,175,685 2,466,594 Common stock available for future grants 1,934,095 67,065 Restricted stock units issued and outstanding 394,750 — Common stock available for ESPP 401,164 — 2008 Stock Plan, as amended (the 2008 Plan) In November 2008, the Company established its 2008 Stock Plan, as amended (the 2008 Plan) which provides for the granting of stock options to employees, directors, and consultants of the Company. Options granted under the 2008 Plan may be either incentive stock options (ISOs) or nonstatutory stock options (NSOs), as determined by the Administrator at the time of grant. The term of each option shall be stated in the Option Agreement; however, the term shall be no more than ten years from the date of the grant. Options granted under the 2008 Plan generally vest 25 % one year after the vesting announcement date and ratably thereafter over the next 36 months . In the case of an ISO granted to an optionee who at the time the option is granted owns stock representing more than 10 % of the voting power of all classes of stock of the Company or any parent subsidiary, the exercise price of the option shall not be less than 110 % of the fair market value of a share on the date of grant. The exercise price of an ISO or NSO granted to any other employee or nonemployee, respectively, shall not be less than 100 % of the fair market value of a share on the date of grant. 2021 Equity Incentive Plan, as amended (the 2021 Plan) In October 2021, the Company established its 2021 Stock Incentive Plan, as amended (the 2021 Plan) which provides granting of stock options, restricted stock, restricted stock units, stock appreciation rights, and performance awards to employees, directors and consultants of the Company. The number of shares of common stock available under the 2021 Plan will be increased by any shares of common stock subject to awards outstanding under the 2008 Plan that on or after the effectiveness of the 2021 Plan, expire or otherwise terminate without having been exercised in full, are tendered to or withheld by the Registrant for payment of an exercise price or for tax withholding obligations, or are forfeited to or repurchased by the Registrant die to failure to vest. Options granted under the 2021 Plan may be either ISOs or NSOs, as determined by the Administrator at the time of grant. The term of each option shall be stated in the Option Agreement; however, the term shall be no more than ten years from the date of the grant. Options granted under the 2021 Plan generally vest 25 % one year after the vesting announcement date and ratably thereafter over the next 36 months . In the case of an ISO granted to an optionee who at the time the option is granted owns stock representing more than 10 % of the voting power of all classes of stock of the Company or any parent subsidiary, the exercise price of the option shall not be less than 110 % of the fair market value of a share on the date of grant. The exercise price of an ISO or NSO granted to any other employee or nonemployee, respectively, shall not be less than 100 % of the fair market value of a share on the date of grant. Options A summary of stock option activity is set forth below (in thousands, except share and per share data): Number of Weighted Weighted Aggregate Outstanding, January 1, 2020 2,482,957 $ 2.96 5.59 2,257 Options granted 451,689 $ 0.61 Options exercised ( 282,813 ) $ 0.73 Options forfeited or cancelled ( 185,239 ) $ 1.28 Outstanding, December 31, 2020 2,466,594 $ 0.61 5.21 — Options granted 1,846,375 $ 11.05 Options exercised ( 1,975,918 ) $ 0.61 Options forfeited or cancelled ( 161,366 ) $ 3.28 Outstanding, December 31, 2021 2,175,685 $ 9.27 8.68 2,856 Shares exercisable December 31, 2021 1,502,978 $ 9.32 8.40 2,066 Vested and expected to vest, December 31, 2021 2,175,685 $ 9.27 8.68 2,856 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock for stock options that were in-the-money as of December 31, 2021 and 2020. The aggregate intrinsic value of stock options exercised during the years end ed December 31, 2021 and December 31, 2020 was $ 1.8 million and less than $ 0.1 million, respectively. The total fair value of options that vested during the years ended December 31, 202 1 and December 31, 2020 was $ 6.0 million and $ 0.6 million, respectively. The options granted during the years ended December 31, 2021 and December 31, 2020 had a weighted-average per share grant-date fair value of $ 8.18 per share and $ 0.37 per share, respectively. As of December 31, 2021, the total unrecognized stock-based compensation expense related to unvest ed stock options was $ 8.9 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.6 years. Early exercise of stock options The terms of the Plan permit the exercise of certain options granted under the Plan prior to vesting, subject to required approvals. The shares are subject to the Company’s lapsing repurchase right upon termination of employment at the original purchase price. The proceeds initially are recorded in accrued current liabilities from the early exercise of stock options and are reclassified to additional paid-in capital as the Company’s repurchase right lapses. During the years ended December 31, 2021 and December 31, 2020, the Company had no repurchases of common stock. As of December 31, 2021 and December 31, 2020, there were 377,709 and 136,032 shares that were subject to repurchase, respectively. The aggregate exercise prices of early exercised shares as of December 31, 2021 and December 31, 2020 were $ 0.2 million and $ 0.1 million, respectively, which were recorded in other current liabilities on the balance sheets. Stock-based compensation associated with awards to employees and non-employees On April 9, 2020, the Company’s Board of Directors approved the repricing of all outstanding stock options for employees, officers and consultants. The Company has treated the repricing as a modification of terms of the options outstanding. The fair value of the modification was determined as the difference in the fair value of each option immediately before and after the repricing using the Black-Scholes option pricing model. The repricing resulted in an incremental compensation cost of less than $ 0.1 million fo r the year ended December 2020. Restricted Stock Units In December 2021 the Company granted 394,750 restricted stock units under 2021 Plan, established by the Company in October 2021. Number of Weighted Average Grant Date Fair Value Unvested, January 1, 2021 — $ — Granted 394,750 $ 5.17 Unvested, December 31, 2021 394,750 $ 5.17 As of December 31, 2021, the total unrecognized stock-based compensation expense related to unvest ed restricted stock units was $ 1.9 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.0 years. 2021 Employee Stock Purchase Plan, as amended (ESPP) In October 2021, the Company adopted the 2021 Employee Stock Purchase Plan (ESPP), which became effective on the business day prior to the effectiveness of the registration statement relating to the IPO. A total of 401,164 shares of common stock were initially reserved for issuance under the ESPP. The offering period and purchase period will be determined by the board of directors. As of December 31, 2021, no offerings had been authorized. Total stock-based compensation expense recognized was as follows (in thousands): Years Ended December 31, 2021 2020 Cost of goods sold $ 274 $ 132 Sales and marketing 2,137 311 Research and development 136 10 General and administrative 4,270 405 Total $ 6,817 $ 858 The above stock-based compensation expense related to the following equity-based awards (in thousands): Years Ended December 31, 2021 2020 Stock options $ 6,722 $ 858 RSU 95 — Total $ 6,817 $ 858 The Company estimated the fair value of stock options using the Black-Scholes option-pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of stock options was estimated using the following weighted-average assumptions: Years Ended December 31, 2021 2020 Expected volatility 72.8 % - 78.0 % 61.6 % - 75.2 % Risk-free interest rate 0.6 % - 1.3 % 0.3 % - 0.7 % Dividend yield 0 % 0 % Expected term 5 - 6 years 5 - 6 years

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	14. Net Loss Per Share Attributable to Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. As the Company reported a net loss for the years ended December 31, 2021 and December 31, 2020, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of potentially dilutive shares would have been antidilutive if included in the calculation: Years Ended December 31, (in thousands, except share and per share amounts) 2021 2020 Numerator Net loss attributable to common stockholders $ ( 21,464 ) $ ( 18,263 ) Denominator: Weighted-average common shares outstanding 7,012,226 968,648 Net loss per share attributable to common stockholders, basic and diluted $ ( 3.06 ) $ ( 18.85 ) The following potentially dilutive securities outstanding in common stock equivalent shares have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company’s net loss: Years Ended December 31, 2021 2020 Redeemable convertible preferred stock — 12,397,838 Redeemable convertible preferred stock warrants — 77,842 Common stock warrants 77,842 — Unvested early exercised common stock options 377,709 136,032 Options to purchase common stock 2,175,685 2,466,594 Unvested restricted stock units 394,750 — Convertible notes* — — * At December 31, 2020, the conversion of the convertible notes into redeemable convertible preferred stock was dependent on the outstanding loan balance including accrued interest and the conversion stock per share price at the date of qualified equity financing, non-qualified equity financing, or a change of control event. These factors were not estimable and the number of redeemable convertible preferred stock was not determinable. There were no conversions of convertible notes to preferred stock for the year ended December 31, 2020.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Employee Benefit Plan	15. Employee Benefit Plan In 2012, the Company implemented a tax deferred savings plan, commonly referred to as a 401(k) plan. Employee contributions are withheld from standard payroll checks and are automatically withdrawn from the Company checking account and deposited into individual employee retirement accounts a few days following each payroll period. There has been no Company matching of employee contributions to the plan through December 31, 2021.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	16. Related Party Transactions A former member of the Company’s Board of Directors owns 100 % of Apical Instruments, Inc. (Apical). Apical was considered a related party until the beginning of May 2021. Apical supplies the Company with the RF Controllers used with its devices. For the years ended December 31, 2021 and 2020 fees charged by Apical for products purchased were less than $ 0.1 million and $ 0.2 million, respectively. As of December 31, 2020, amounts owed to Apical were less than $ 0.1 million, respectively. The Company has issued convertible notes to certain redeemable convertible preferred stockholders (see Note 8).

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events No material subsequent events have been identified.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The accompanying financial statements have been prepared using accounting principles generally accepted in the United States of America (GAAP).
Reverse Stock Split	Reverse Stock Split On October 14, 2021, the Company effected a 1 -for-6.046 reverse stock split of its outstanding common stock and redeemable convertible preferred stock. Upon the effectiveness of the reverse stock split, all issued and outstanding shares of common stock options to purchase common stock, warrants, instruments convertible to shares, redeemable convertible preferred stock and related share data and per share amounts contained in the accompanying financial statements were retroactively revised to reflect this reverse stock split for all periods presented. The par value of the authorized stock was not adjusted as a result of the reverse stock split.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Significant estimates and assumptions include accounts receivable allowances, inventory allowances, recoverability of long-term assets, valuation of equity instruments and equity-linked instruments, valuation of common stock, stock-based compensation, valuation of the redeemable convertible preferred stock warrant liability and derivative liabilities, valuation and estimated useful lives of intangible assets, deferred tax assets and related valuation allowances, and impact of contingencies.
Segments	Segments The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Fair Value of Financial Instruments	Fair value of financial instruments The carrying amounts of the Company’s financial instruments, including cash and cash equivalents and restricted cash, accounts receivable, accounts payable, and accrued liabilities, approximate their fair value due to the short-term nature of these assets and liabilities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loans approximate their fair values and is classified as a Level 2 liability.
Concentration of Credit Risk	Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (FDIC) insured limits. The Company earns revenue from sale of disposable devices and controllers to customers such as hospitals, ACS and physician offices. The Company’s accounts receivable are derived from revenue earned from customers. The Company performs ongoing credit evaluations of its customers’ financial condition and generally requires no collateral from its customers. As of December 31, 2021 and 2020, and for the years then ended, no customer accounted for more than 10% of accounts receivable or revenue.
Concentration of Suppliers	Concentration of suppliers The Company purchases certain components of its products from a single or small number of suppliers. A change in or loss of these suppliers could cause a delay in filling customer orders and a possible loss of sales, which could adversely affect results of operations; however, management believes that suitable replacement suppliers could be obtained in such an event.
Cash and Cash Equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents, which include money market funds.
Restricted Cash	Restricted cash As of December 31, 2021 and 2020, cash of $ 7.8 million was restricted from withdrawal. Restricted cash consists of collateral for letters of credit issued in connection with litigation, real estate leases, and corporate credit cards (See Note 9).
Accounts Receivable and Allowances	Accounts receivable and allowances Accounts receivable are generally from hospitals and ASCs and are stated at amounts billed less allowances for doubtful accounts. The Company continually monitors customer payments and maintains an allowance for estimated losses resulting from a customer’s inability to make required payments. The Company considers factors such as historical experience, credit quality, age of the accounts receivable balances, geographic-related risks and economic conditions that may affect a customer’s ability to pay. Accounts receivable are written off when the Company deems individual balances are no longer collectible. As of December 31, 2021 and 2020, accounts receivable is presented net of an allowance for doubtful accounts of $ 0.5 million and $ 0.4 million, respectively. For the years ended December 31, 2021 and 2020, the Company recorded a provision for bad debts of less than $ 0.2 million and $ 0.3 million, respectively
Inventory	Inventory Inventory consist primarily of disposable devices, controllers, and components as raw materials and finished goods and are stated at the lower of cost or net realizable value. Cost is determined using standard cost based on the first-in, first-out method (FIFO) for all inventories. The Company periodically assesses the recoverability of all inventories to determine whether adjustments for impairment are required. The Company evaluates the related commercial mix of finished goods and other general obsolescence and impairment criteria in assessing the recoverability of the Company’s inventory and records a provision for excess, expired, and obsolete inventory based primarily on estimates of forecasted revenues. A significant change in the timing or level of demand for products as compared to forecasted amounts may result in recording additional provision for excess, expired, and obsolete inventory in the future. For the years ended December 31, 2021 and 2020, the Company did no t record a provision for excess or obsolete inventory.
Property and Equipment, Net	Property and equipment, net Property and equipment is recorded at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the estimated useful lives of the assets ( two to seven years ) or the lease term of the leasehold improvements, whichever is lower. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation and amortization are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period such gain or loss is realized.
Intangible Assets	Intangible assets Intangible assets arising from business combinations, such as trade names, customer relationships and developed technology, are initially recorded at estimated fair value. Amortization is computed over the estimated useful life of each asset on a straight-line basis. The Company determines the useful lives of identifiable intangible assets after considering the facts and circumstances related to each intangible asset. Factors the Company considers when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, the Company’s long-term strategy for using the asset, any laws or other local regulations which could impact the useful life of the asset and other economic factors, including competition and specific market conditions. The useful lives of the major intangible asset classes are as follows: Trademarks 6.5 Developed technology 10 Customer relationships 3
Business Combination	Business combination Business combinations are accounted for under the acquisition method. The Company recognizes the assets acquired and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. Contingent consideration is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using a Monte Carlo simulation. These cash flow projections are discounted with an appropriate risk-adjusted rate. The fair value of the contingent consideration liability is remeasured at each reporting period with the change in the fair value recorded as a component of operating expenses in the statements of operations until the underlying contingency is resolved. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded. The Company assesses the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant estimates and assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset, future cash inflows and outflows, probabilities of success, asset lives, and the appropriate discount rates. The Company uses the income approach to determine the fair value of developed technology acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. The Company bases its revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected product introductions by competitors. Developed technology represents patented and unpatented technology and know-how. The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships and trade names. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names. Any excess fair value of the net tangible and intangible assets acquired over the purchase price is recorded as bargain purchase gain in the statements of operations at the acquisition closing date. During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed. After the measurement period, all adjustments are recorded in the statements of operations as operating expenses or income. Transaction costs and restructuring costs associated with a business combination are expensed as incurred.
Impairment of Long-lived Assets	Impairment of long-lived assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There has been no impairment of long-lived assets during the years ended December 31, 2021 and 2020.
Leases	Leases The Company leases its facilities and meets the requirements to account for these leases as operating leases. The Company recognizes rent expense on a straight-line basis over the non-cancellable lease term. Where leases contain escalation clauses, rent abatements or concessions, such as rent holidays and landlord or tenant incentives or allowances, the Company applies them in the determination of straight-line rent expense over the lease term. The Company records the difference between the rent paid and the straight-line rent as a deferred rent liability.
Redeemable Convertible Preferred Stock	Redeemable convertible preferred stock The Company records all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because while it is not mandatorily redeemable, in certain events considered not solely within the Company’s control, such as a merger, acquisition or sale of all or substantially all of the Company’s assets (each, a deemed liquidation event), the redeemable convertible preferred stock will become redeemable at the option of the holders of at least a majority of the then-outstanding preferred shares. All outstanding shares of the convertible preferred stock converted into common stock upon effectiveness of the IPO.
Redeemable Convertible Preferred Stock Warrants and Common Stock Warrants	Redeemable convertible preferred stock warrants and common stock warrants Freestanding preferred stock warrants are accounted for in accordance with Financial Accounting Standard Board (FASB) ASU Topic 480, Distiguishing Liabilities from Equity (ASC 480) and classified as liabilities on the balance sheet because the underlying preferred stock shares are redeemable upon occurrence of a deemed liquidation event. Preferred stock warrants are subject to re-measurement at each balance sheet date with the change in fair value, if any, recognized in other income (expense), net in the statements of operations. All outstanding preferred stock warrants converted into common stock warrants upon effectiveness of the IPO. Upon closing of the IPO, the warrant liability was reclassified to additional paid-in capital as the common stock warrants meet all criteria for equity classification.
Derivative Liabilities	Derivative liabilities Embedded derivatives that are required to be bifurcated from their host contract are evaluated and valued separately from the debt instrument. Under the Company’s Credit Agreement (the Ares Agreement) with Ares Capital Corporation and Ares Direct Finance I LP (collectively Ares) (Note 8), upon the occurrence of specified prepayment trigger events, including a default or a change in control, the Company may be required to make mandatory prepayments of the borrowings. The prepayment premium is considered an embedded derivative, as the holder of the loan may exercise the option to require prepayment by the Company. The mandatory prepayment derivative liability is recorded at fair value upon entering into the Ares Agreement and is subject to remeasurement to fair value at each balance sheet date, with any changes in fair value recognized in the statements of operations. The Company’s convertible notes contain embedded features (Note 8)—a qualified financing put, non-qualified financing put, and change of control put features—that are bifurcated and accounted for as derivative liabilities and recorded as a debt discount on the note issuance date. Debt discount is reported as a direct deduction to the carrying amount of the convertible notes and amortized using the effective interest rate over the life of the convertible notes as interest expense. The embedded derivative features are recorded at fair value upon entering into the note purchase agreements and are subject to remeasurement to fair value at each balance sheet date, with any changes in fair values recognized in the statements of operations. In connection with execution of the CIBC Agreement, the Company entered into a separate Success Fee Agreement with CIBC (see Note 8). In the event of a sale or other disposition by the Company of all or substantially all of its assets, a merger or consolidation, or an initial public offering (a Liquidity Event), before the termination of the agreement, the Company agreed to pay a fee to CIBC equal to $ 0.4 million (Success Fee) . This agreement has been identified as a freestanding derivative and is subject to remeasurement to its fair value at each reporting date or repayment or expiration, with any changes in fair values recognized in the statements of operations. In connection with the IPO, the derivative liability was settled upon the Company paying the Success Fee of $ 0.4 million to CIBC pursuant to the Success Fee Agreement.
Debt Discount	Debt discount The Company records the value of original issuance discounts, issuance costs, and discounts attributable to warrants or bifurcated derivatives associated with debt on issuance, as a debt discount, which is presented net of the outstanding balance of debt on the balance sheet and amortized as an adjustment to interest expense over the borrowing term using the effective interest method.
Revenue Recognition	Revenue recognition The Company generates revenue primarily from the sale of disposable devices and controllers that treat the root causes of abnormal uterine bleeding (AUB). The Company invoices hospitals, ASCs, and physician offices for the sold products and pays commissions to the sales representatives. The Company also provides controllers to customers under evaluation and long-term placement agreements. Under these agreements, the Company delivers the controller to the customer’s facility without a fee and the customer agrees to purchase disposable products at a stated price over the term of the agreement. The Company retains title to the controllers. The Company, in general, does not enforce a minimum purchase requirement under these agreements. Terms of the long-term placement agreements range from several months to multiple years and may be extended or terminated upon mutual agreement. These types of agreements include an embedded lease, which is generally a cancellable operating lease, for the right to use a controller. The Company also offers extended warranty agreements to customers for controller defects, malfunctions, or system failures. In line with ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies performance obligations. A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party’s rights regarding the products to be transferred and identifies the payment terms related to these products, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. The Company identifies performance obligations in contracts with customers, which may include its products and implied promise to provide the free leased controller. The transaction price is determined based on the amount the Company is expected to be entitled to in exchange for transferring the promised products to the customer. The Company is entitled to the total consideration for the products ordered by customers, net of transaction price adjustments. The Company’s payment terms to customers are generally net 30 days. Payment terms fall within the guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. Assuming all other revenue recognition criteria are met, revenue is recognized when control of the Company’s products transfers to the customer. For sales where the Company’s sales representative hand delivers products directly to the hospital or ASC, control transfers to the customer upon such delivery. For sales where products are shipped, control is transferred either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. The Company recognizes revenue that has been allocated to free leased controllers concurrent with the sale of disposable devices as the lease is cancellable by either party with 30 days’ notice. The amounts allocated to leased controllers are insignificant. As permitted under the practical expedient, the Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The Company accepts product returns at its discretion or if the product is defective as manufactured. Historically, the actual product returns have been insignificant. However, if returns should be become material, the Company will use the expected-value method for estimating returns based on historical data. The Company elected to treat shipping and handling costs as a fulfillment cost and includes them in the cost of goods sold as incurred. In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as revenue. Extended warranty arrangements are recognized ratably over the extended warranty period. For the years ended December 31, 2021 and 2020 warranty revenue was $ 0.1 million and less than $ 0.1 million, and considered insignificant. The Company’s contract liabilities consist of deferred revenue for remaining performance obligations by the Company to the customer after delivery, which is $ 0.1 million as of December 31, 2021. Deferred revenue as of December 31, 2020 was $ 0.2 million, which was recognized as revenue in 2021.
Contract Costs	Contract costs The Company applies the practical expedient to recognize the incremental costs of obtaining a contract as expense when incurred because the expense is incurred at a point in time and the amortization period is less than one year, as the Company does not enter into long-term sales contracts. These incremental costs include sales commissions paid to the Company’s independent sales agents or internal sales representatives. Commissions are recorded as selling expenses.
Cost of Goods Sold	Cost of goods sold The Company manufactures certain products at its facility and purchases other products from third-party manufacturers. Cost of goods sold consists primarily of the third-party manufacturing costs, materials and assembly, direct labor, and charges for excess, obsolete, and non-sellable inventory. Cost of goods sold also includes allocated overhead for indirect labor, depreciation, rent, and information technology.
Product Warranties	Product warranties The Company generally offers a one-year warranty for its products. The Company provides for the estimated cost of product warranties at the time product revenue is recognized. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. Costs to perform warranty obligations were less than $ 0.1 million for the years ended December 31, 2021 and 2020.
Research and Development	Research and development Research and development (R&D) expenses are charged to operations when incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment, depreciation, and utilities.
Income Taxes	Income taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between the carrying amounts of assets and liabilities used for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company’s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made. The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances, and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50.0% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit).
Stock-based Compensation	Stock-based compensation We have granted stock-based awards, consisting of stock options restricted stock units to employees and certain non-employee consultants and certain members of our board of directors. The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options and restricted stock units. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. We use the fair value of our common stock to determine the fair value of restricted stock awards . The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.
Net Loss per Share Attributable to Common Stockholders	Net loss per share attributable to common stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders, by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrants, convertible notes, common stock subject to repurchase, restricted stock units and common stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security because it participates in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of redeemable convertible preferred stock do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for the years ended December 31, 2021 and 2020, diluted net loss per common share is the same as basic net loss per common share for the periods presented.
JOBS Act Accounting Election	JOBS Act accounting election The Jumpstart Our Business Startups Act of 2012, (the JOBS Act) permits an “emerging growth company” to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. The Company has elected to use this extended transition period under the JOBS Act. As a result, its financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Useful Lives of Major Intangible Assets	The useful lives of the major intangible asset classes are as follows: Trademarks 6.5 Developed technology 10 Customer relationships 3

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Schedule of Disaggregation of Revenue	Disaggregation of revenue Years Ended December 31, 2021 2020 Minerva ES 46.8 % 55.4 % Genesys HTA 31.6 % 28.5 % Symphion 20.6 % 15.3 % Other 1.0 % 0.9 % 100 % 100 %
Schedule of Contract Balance	The Company’s contract balances consist of the following (in thousands): December 31, 2021 2020 Accounts receivable $ 7,292 $ 8,379 Contract liability—current (see "Note 6") $ 206 $ 219

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2021 and 2020 (in thousands): December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 38,522 $ — $ — $ 38,522 Total financial assets $ 38,522 $ — $ — $ 38,522 Liability: Contingent consideration liability $ — $ — $ 14,094 $ 14,094 Total financial liabilities $ — $ — $ 14,094 $ 14,094 December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 14,638 $ — $ — $ 14,638 Total financial assets $ 14,638 $ — $ — $ 14,638 Liability: Derivative liabilities $ — $ — $ 38,007 $ 38,007 Contingent consideration liability — — 23,667 23,667 Redeemable convertible preferred stock warrant liability — — 42 42 Total financial liabilities $ — $ — $ 61,716 $ 61,716
Schedule Of Convertible Notes Derivative Liabilities Determined Using Assumptions	The convertible notes derivative liabilities were determined using the following assumptions: December 31, 2020 Expected exit date 6/30/2022 Discount rate 21.0 %
Schedule of Change in Fair Value of the Redeemable Convertible Preferred Stock Warrant Liability, Derivative Liabilities and Contingent Consideration Liability	The change in fair value of the redeemable convertible preferred stock warrant liability, derivative liabilities and contingent consideration liability are summarized below (in thousands) Redeemable Derivative Contingent Beginning fair value, January 1, 2020 $ 75 $ 39,499 $ — Recognition — 6,848 23,842 Change in fair value ( 33 ) ( 8,340 ) ( 175 ) Ending fair value, December 31, 2020 42 38,007 23,667 Beginning fair value, January 1, 2021 42 38,007 23,667 Change in fair value 328 ( 38,007 ) 427 Payment of Development Milestone — — ( 10,000 ) Conversion into common stock warrant ( 370 ) — — Ending fair value, December 31, 2021 $ — $ — $ 14,094

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2021
Balance Sheet Components [Abstract]
Schedule of Cash and Cash Equivalents	The Company’s cash and cash equivalents consist of the following (in thousands): December 31, 2021 2020 Cash $ 2,086 $ 2,721 Cash equivalents: Money market funds 38,522 14,638 Total cash and cash equivalents $ 40,608 $ 17,359
Schedule of Inventory	Inventory consists of the following (in thousands): December 31, 2021 2020 Finished goods $ 9,495 $ 5,068 Component materials 6,187 5,133 Total inventory $ 15,682 $ 10,201
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2021 2020 Prepaid expenses $ 1,264 $ 1,794 Prepaid insurance 2,726 122 Other current assets 149 363 Total prepaid expenses and other current assets $ 4,139 $ 2,279
Property and Equipment, Net	Property and equipment, net consist of the following (in thousands): December 31, Useful life (years) 2021 2020 Computers and software 2 $ 730 $ 653 Machinery and equipment 3 997 954 Furniture and fixtures 7 48 48 Tools and dies 2 941 936 Construction in progress — 428 — Equipment under customer usage agreements 3 10,612 7,918 Leasehold improvements Lesser of useful life or lease term 155 155 13,911 10,664 Less: accumulated depreciation and amortization ( 9,317 ) ( 7,784 ) Property and equipment, net $ 4,594 $ 2,880
Schedule of Intangible Assets, Net	Intangible asset, net consist of the following (in thousands): December 31, 2021 Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks $ 3,969 $ ( 992 ) $ 2,977 Developed technology 30,819 ( 5,008 ) 25,811 Customer relationships 13,466 ( 7,294 ) 6,172 Other intangible assets 10 — 10 Total intangible assets $ 48,264 $ ( 13,294 ) $ 34,970 December 31, 2020 Gross Carrying Value Accumulated Amortization Net Carrying Value Trademarks $ 3,969 $ ( 382 ) $ 3,587 Developed technology 30,819 ( 1,926 ) 28,893 Customer relationships 13,466 ( 2,805 ) 10,661 Total intangible assets $ 48,254 $ ( 5,113 ) $ 43,141
Schedule of Future Amortization Expense of Intangible Assets	Future amortization expense of intangible assets as of December 31, 2021 is as follows (in thousands): Year Ending December 31, 2022 $ 8,182 2023 5,376 2024 3,693 2025 3,693 Thereafter 14,016 Total $ 34,960
Schedule of Accrued Compensation	Accrued compensation consists of the following (in thousands): December 31, 2021 2020 Accrued vacation $ 1,469 $ 1,184 Accrued bonuses 1,307 831 Accrued commissions 665 828 Other accrued personnel related expenses 77 46 Total accrued compensation $ 3,518 $ 2,889
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): December 31, 2021 2020 Accrual for litigation $ 7,203 $ 7,203 Accrued professional fees 974 824 Accrued sales and use taxes 657 754 Deferred rent 277 445 Accrual for inventory in transit 119 602 Contract liability 206 219 Others 1,037 157 Total accrued liabilities $ 10,473 $ 10,204

Business Combination (Tables)

Business Combination (Tables)	12 Months Ended
	Dec. 31, 2021
Business Combination Description [Abstract]
Summary of Purchase Consideration	The summary of the purchase consideration is as follows (in thousands, except shares and per share amounts): Description Amount Closing stock consideration — 1,331,411 shares of Series D redeemable convertible preferred stock at $ 2.06 per share $ 2,737 Cash consideration 15,000 Delayed cash consideration 15,000 Development Milestone payment (a) 8,615 Revenue Milestone payments (b) 15,227 Total purchase consideration $ 56,579
Schedule of Purchase Price of Acquired Assets and Liabilities	The following table summarizes the allocation of the purchase price based on the estimated fair values of the acquired assets and assumed liabilities as of May 12, 2020 (in thousands): Net assets acquired: Inventory $ 7,846 Other receivable 271 Property and equipment 999 Trade names 3,969 Customer relationships 13,466 Developed technology 30,819 Warranty liability ( 16 ) Deferred tax liability ( 132 ) Negative goodwill ( 643 ) Purchase price $ 56,579
Components of Identifiable Intangible Assets Acquired	The components of identifiable intangible assets acquired were as follows (in thousands) : Useful lives (4) Value as of Trademarks (1) 6.5 $ 3,969 Developed technology (2) 10 30,819 Customer relationships (3) 3 13,466 Total identifiable intangible assets acquired $ 48,254 (1) The relief from royalty method of the income approach was used to estimate the fair value of the trademarks. (2) Developing technology was valued using the excess earnings method (3) Customer relationship assets represent the expected profits to be generated from the customer contracts, incorporating estimated customer retention rates. (4) The estimated useful lives were determined based on the future economic benefit expected to be received from the assets .

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Instrument [Line Items]
Schedule of Convertible Note	The convertible notes consist of the following (in thousands): December 31, 2020 Principal $ 69,245 Less: debt issuance costs ( 38 ) Less: debt discount ( 8,145 ) Accrued interest 5,134 Convertible notes $ 66,196
Schedule of Contractual Maturities of Financing Obligations	As of December 31, 2021, the aggregate future payments under the CIBC Loan (including interest payments) are as follows (in thousands): 2022 $ 2,300 2023 4,457 2024 14,807 2025 14,060 2026 12,229 Total 47,853 Less: unamortized debt discounts and issuance costs ( 915 ) Less: interest ( 7,664 ) Term loan $ 39,274
Ares Term Loan
Debt Instrument [Line Items]
Schedule of Debt	The Ares Loan consists of the following (in thousands): December 31, 2020 Term loan principal $ 31,878 Less: debt issuance cost and debt discount ( 4,120 ) Add: exit fee 312 Term loan $ 28,070
CIBC Term Loan
Debt Instrument [Line Items]
Schedule of Debt	The CIBC Loan consists of the following (in thousands): December 31, 2021 Term loan principal $ 40,000 Less: Debt issuance cost and debt discount ( 915 ) Accrued interest 189 Term loan $ 39,274

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The future minimum rental obligations required under non-cancellable lease on December 31, 2021 are as follows (in thousands): 2022 $ 846 2023 358 Total minimum lease payments $ 1,204

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Summary of Reconciliation Between Federal Statutory Rate and Effective Tax Rate	The reconciliation between the federal statutory rate and the Company’s effective tax rate is summarized below: Years Ended December 31, 2021 2020 Federal statutory rate 21.00 % 21.00 % State blended rate 4.99 % 3.34 % Stock-based compensation ( 3.61 %) ( 0.77 %) Gain (loss) on debt extinguishment ( 8.53 %) —% Other permanent items ( 0.47 %) ( 0.13 %) Change in valuation allowance ( 62.41 %) ( 25.48 %) Convertible debt embedded derivative 44.95 % 1.94 % Other 4.02 % 0.82 % Effective tax rate ( 0.06 %) 0.72 %
Summary of Tax Effects of Temporary Differences and Carryforwards of Deferred Tax Deferred Tax and Liabilities	The tax effects of temporary differences and carryforwards of the deferred tax assets and liabilities are presented below (in thousands): December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 50,494 $ 44,568 Depreciation and amortization 4,656 3,375 Accruals and reserves 3,577 2,666 Interest expense limitation carryforward 2,229 — Research and development credits 2,250 2,197 Gross deferred tax assets $ 63,206 $ 52,806 Less: valuation allowance ( 63,206 ) ( 49,817 ) Net deferred tax assets $ — $ 2,989 Deferred tax liability: Convertible debt embedded derivative — ( 2,989 ) Total $ — $ —
Summary of Changes in Unrecognized Tax Benefits	The following table reflects changes in the unrecognized tax benefits since January 1, 2020 (in thousands): December 31, 2021 2020 Gross amount of unrecognized tax benefits as of the beginning of the period $ 447 $ 431 Increases related to current year tax provisions 18 16 Gross amount of unrecognized tax benefits as of the end of the period $ 465 $ 447

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred Stock Warrants and Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Class Of Stock [Line Items]
Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions	The fair value of stock options was estimated using the following weighted-average assumptions: Years Ended December 31, 2021 2020 Expected volatility 72.8 % - 78.0 % 61.6 % - 75.2 % Risk-free interest rate 0.6 % - 1.3 % 0.3 % - 0.7 % Dividend yield 0 % 0 % Expected term 5 - 6 years 5 - 6 years
Summary of Outstanding Warrants to Purchase Shares of Common Stock	As of December 31, 2021, the Company`s outstanding warrants to purchase shares of common stock, consisted of the following: Issuance Date Number of Shares of Common Stock Issuable Exercise Price Classification Expiration Date May 9, 2017 33,964 $ 11.31 Equity May 8, 2027 July 19, 2019 43,878 $ 11.31 Equity July 18, 2029 77,842
Series D Redeemable Convertible Preferred Stock Warrants
Class Of Stock [Line Items]
Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions	The redeemable convertible preferred stock warrant liability was valued using the following assumptions under the Black-Scholes option-pricing model: October 22, 2021 December 31, 2020 Expected dividends 0 % 0 % Expected volatility 51.4 % - 54.7 % 48.2 % - 52.4 % Risk-free interest rate 1.3 % - 1.5 % 0.6 % - 0.8 % Expected warrant life 5.5 - 7.7 years 6.4 - 8.6 years

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2021
Temporary Equity Disclosure [Abstract]
Summary of Redeemable Convertible Preferred Stock	As of December 31, 2020, redeemable convertible preferred stock consists of the following (in thousands, except per share and share amounts): Series Number of Shares Authorized Number of Shares Issued and Outstanding Carrying Value Liquidation Preference per Share Liquidation Value Series A 2,725,000 450,692 $ 2,725 $ 6.05 $ 2,725 Series B 4,083,542 675,397 5,845 8.89 6,003 Series C 13,995,537 2,223,888 24,980 11.31 25,144 Series D 100,928,318 9,047,861 89,705 11.31 102,296 Total 121,732,397 12,397,838 $ 123,255 $ 136,168

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Shares Reserved for Future Issuance	The Company has reserved shares of common stock for future issuances as follows: December, 31 2021 2020 Series A redeemable convertible preferred stock outstanding — 450,692 Series B redeemable convertible preferred stock outstanding — 675,397 Series C redeemable convertible preferred stock outstanding — 2,223,888 Series D redeemable convertible preferred stock outstanding — 9,047,861 Warrants to purchase Series D redeemable convertible preferred stock — 77,842 Warrants to purchase common stock 77,842 — Common stock options issued and outstanding 2,175,685 2,466,594 Common stock available for future grants 1,934,095 67,065 Restricted stock units issued and outstanding 394,750 — Common stock available for ESPP 401,164 —
Schedule of Stock Option Activity	A summary of stock option activity is set forth below (in thousands, except share and per share data): Number of Weighted Weighted Aggregate Outstanding, January 1, 2020 2,482,957 $ 2.96 5.59 2,257 Options granted 451,689 $ 0.61 Options exercised ( 282,813 ) $ 0.73 Options forfeited or cancelled ( 185,239 ) $ 1.28 Outstanding, December 31, 2020 2,466,594 $ 0.61 5.21 — Options granted 1,846,375 $ 11.05 Options exercised ( 1,975,918 ) $ 0.61 Options forfeited or cancelled ( 161,366 ) $ 3.28 Outstanding, December 31, 2021 2,175,685 $ 9.27 8.68 2,856 Shares exercisable December 31, 2021 1,502,978 $ 9.32 8.40 2,066 Vested and expected to vest, December 31, 2021 2,175,685 $ 9.27 8.68 2,856
Schedule of Restricted Stock Units	In December 2021 the Company granted 394,750 restricted stock units under 2021 Plan, established by the Company in October 2021. Number of Weighted Average Grant Date Fair Value Unvested, January 1, 2021 — $ — Granted 394,750 $ 5.17 Unvested, December 31, 2021 394,750 $ 5.17
Summary of Stock-Based Compensation Expense	Total stock-based compensation expense recognized was as follows (in thousands): Years Ended December 31, 2021 2020 Cost of goods sold $ 274 $ 132 Sales and marketing 2,137 311 Research and development 136 10 General and administrative 4,270 405 Total $ 6,817 $ 858 The above stock-based compensation expense related to the following equity-based awards (in thousands): Years Ended December 31, 2021 2020 Stock options $ 6,722 $ 858 RSU 95 — Total $ 6,817 $ 858
Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions	The fair value of stock options was estimated using the following weighted-average assumptions: Years Ended December 31, 2021 2020 Expected volatility 72.8 % - 78.0 % 61.6 % - 75.2 % Risk-free interest rate 0.6 % - 1.3 % 0.3 % - 0.7 % Dividend yield 0 % 0 % Expected term 5 - 6 years 5 - 6 years

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. As the Company reported a net loss for the years ended December 31, 2021 and December 31, 2020, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of potentially dilutive shares would have been antidilutive if included in the calculation: Years Ended December 31, (in thousands, except share and per share amounts) 2021 2020 Numerator Net loss attributable to common stockholders $ ( 21,464 ) $ ( 18,263 ) Denominator: Weighted-average common shares outstanding 7,012,226 968,648 Net loss per share attributable to common stockholders, basic and diluted $ ( 3.06 ) $ ( 18.85 )
Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding	The following potentially dilutive securities outstanding in common stock equivalent shares have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company’s net loss: Years Ended December 31, 2021 2020 Redeemable convertible preferred stock — 12,397,838 Redeemable convertible preferred stock warrants — 77,842 Common stock warrants 77,842 — Unvested early exercised common stock options 377,709 136,032 Options to purchase common stock 2,175,685 2,466,594 Unvested restricted stock units 394,750 — Convertible notes* — — * At December 31, 2020, the conversion of the convertible notes into redeemable convertible preferred stock was dependent on the outstanding loan balance including accrued interest and the conversion stock per share price at the date of qualified equity financing, non-qualified equity financing, or a change of control event. These factors were not estimable and the number of redeemable convertible preferred stock was not determinable. There were no conversions of convertible notes to preferred stock for the year ended December 31, 2020.

Formation and Business of the_2

Formation and Business of the Company - Additional Information (Details) - USD ($)	Oct. 21, 2021	Oct. 20, 2021	Dec. 31, 2021	Dec. 31, 2020	Oct. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares authorized	100,000,000		100,000,000	144,406,928
Common stock, par value	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000		5,000,000	0
Preferred stock, par value	$ 0.001		$ 0.001	$ 0.001
Proceeds from initial public offering, net of underwriting discount and commission			$ 69,750,000
Aggregate outstanding principal and accrued interest of convertible promissory notes				$ 0
Net Loss			21,464,000	18,263,000
Accumulated deficit			(249,556,000)	(228,092,000)
Cash and cash equivalents			$ 40,608,000	$ 17,359,000
Redeemable convertible preferred stock converted	12,397,838	19,404,066
Convertible Promissory Notes
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate outstanding principal and accrued interest of convertible promissory notes		$ 79,200,000
Initial Public Offering
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred offering costs	$ 3,200,000
Redeemable Convertible Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Conversion of preferred stock		7,006,228
Conversion price per share		$ 11.31
Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares sold and issued			6,250,000
Common Stock | Initial Public Offering
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares sold and issued	6,250,000
Shares issued offering price per share	$ 12
Aggregate gross proceeds	$ 75,000,000
Proceeds from initial public offering, net of underwriting discount and commission	$ 69,800,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	Oct. 14, 2021	Oct. 08, 2021USD ($)	Dec. 31, 2021USD ($)CustomerSegment	Dec. 31, 2020USD ($)Customer	Oct. 26, 2021USD ($)
Financing Receivable Impaired [Line Items]
Reverse stock split	1-for-6.046
Reverse stock split ratio	0.165
Number of reportable segment | Segment			1
Number of operating segment | Segment			1
Number of customer accounted for accounts receivable or revenue | Customer			0	0
Restricted cash			$ 7,807,000	$ 7,807,000
Allowance for doubtful accounts			500,000	400,000
Provision for bad debts				300,000
Provision for excess or obsolete inventory			0	0
Impairment of long-lived assets			0	0
Payment of success fee			400,000
Revenues			52,103,000	37,768,000
Deferred revenue			100,000	200,000
Warranty
Financing Receivable Impaired [Line Items]
Revenues			100,000
CIBC Agreement
Financing Receivable Impaired [Line Items]
Payment of success fee		$ 400,000
Success fee derivative liability					$ 400,000
Maximum
Financing Receivable Impaired [Line Items]
Provision for bad debts			$ 200,000
Property and equipment, useful life			7 years
Costs to perform warranty obligations			$ 100,000	100,000
Maximum | Warranty
Financing Receivable Impaired [Line Items]
Revenues				$ 100,000
Minimum
Financing Receivable Impaired [Line Items]
Property and equipment, useful life			2 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Useful Lives of Major Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2021
Trademarks
Finite-Lived Intangible Assets [Line Items]
Useful lives of intangible assets	6 years 6 months
Developed Technology
Finite-Lived Intangible Assets [Line Items]
Useful lives of intangible assets	10 years
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Useful lives of intangible assets	3 years

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements - Additional Information (Details) $ in Millions	Dec. 31, 2021USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Expects to recognize operating lease right-of-use asset	$ 0.9
Expects to recognize operating lease liability	$ 1.2
ASU 2018-13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, early adoption [true false]	true
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
ASU 2019-12
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true

Revenue - Schedule of Disaggreg

Revenue - Schedule of Disaggregation of Revenue (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue, percentage	100.00%	100.00%
Minerva ES
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue, percentage	46.80%	55.40%
Genesys HTA
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue, percentage	31.60%	28.50%
Symphion
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue, percentage	20.60%	15.30%
Other
Disaggregation Of Revenue [Line Items]
Disaggregation of revenue, percentage	1.00%	0.90%

Revenue - Additional Informatio

Revenue - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Percentage of revenue subject to point-in-time recognition	99.00%	99.00%
Minimum percentage of sale extended warranties on capital equipment	1.00%
Maximum percentage of total revenue derived from sale of single-use (disposable) products	98.00%

Revenue - Schedule of Contract

Revenue - Schedule of Contract Balance (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Contract With Customer Asset And Liability [Abstract]
Accounts receivable	$ 7,292	$ 8,379
Contract liability-current (see "Note 6")	$ 206	$ 219

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Cash equivalents:
Money market funds	$ 38,522	$ 14,638
Total financial assets	38,522	14,638
Liability:
Derivative liabilities		38,007
Contingent consideration liability	14,094	23,667
Redeemable convertible preferred stock warrant liability		42
Total financial liabilities	14,094	61,716
Level 1
Cash equivalents:
Money market funds	38,522	14,638
Total financial assets	38,522	14,638
Level 3
Liability:
Derivative liabilities		38,007
Contingent consideration liability	14,094	23,667
Redeemable convertible preferred stock warrant liability		42
Total financial liabilities	$ 14,094	$ 61,716

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Details) - USD ($)	Oct. 31, 2021	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liabilities		$ 38,007,000
Convertible Note
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of aggregate outstanding derivative instrument		$ 33,500,000
2018, 2019 and 2020 Notes
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liabilities	$ 0

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule Of Convertible Notes Derivative Liabilities Determined Using Assumptions (Details)	12 Months Ended
	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected exit date	Jun. 30, 2022
Measurement Input, Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Discount rate	21

Fair Value - Summary of Redeema

Fair Value - Summary of Redeemable Convertible Preferred Stock Warrant Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Redeemable Convertible Preferred Stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning fair value	$ 42	$ 75
Change in fair value	328	(33)
Conversion into common stock warrant	(370)
Ending fair value		42
Derivative Liabilities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning fair value	38,007	39,499
Recognition		6,848
Change in fair value	(38,007)	(8,340)
Ending fair value		38,007
Contingent Consideration Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning fair value	23,667
Recognition		23,842
Change in fair value	427	(175)
Payment of Development Milestone	(10,000)
Ending fair value	$ 14,094	$ 23,667

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Components [Abstract]
Cash	$ 2,086	$ 2,721
Cash equivalents:
Money market funds	38,522	14,638
Total cash and cash equivalents	$ 40,608	$ 17,359

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Components [Abstract]
Finished goods	$ 9,495	$ 5,068
Component materials	6,187	5,133
Total inventory	$ 15,682	$ 10,201

Balance Sheet Components - Prep

Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Components [Abstract]
Prepaid expenses	$ 1,264	$ 1,794
Prepaid insurance	2,726	122
Other current assets	149	363
Total prepaid expenses and other current assets	$ 4,139	$ 2,279

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 13,911	$ 10,664
Less: accumulated depreciation and amortization	(9,317)	(7,784)
Property and equipment, net	4,594	2,880
Computer and Software
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 730	653
Property and equipment, useful life	2 years
Machinery and Equipment
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 997	954
Property and equipment, useful life	3 years
Furniture and Fixtures
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 48	48
Property and equipment, useful life	7 years
Tools and Dies
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 941	936
Property and equipment, useful life	2 years
Construction in Progress
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 428
Equipment Under Customer Usage Agreements
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 10,612	7,918
Property and equipment, useful life	3 years
Leasehold Improvements
Balance Sheet Components [Line Items]
Property and equipment, gross	$ 155	$ 155
Property and equipment, useful life, description	Lesser of useful life or lease term

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Components [Line Items]
Depreciation and amortization expense on property and equipment	$ 2.4	$ 2
Amortization expense on intangible assets	8.2	5.1
Equipment Under Customer Usage Agreements
Balance Sheet Components [Line Items]
Depreciation and amortization expense on property and equipment	$ 2.1	$ 1.6

Balance Sheet Components - Sc_4

Balance Sheet Components - Schedule of Intangible Asset, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Components [Line Items]
Gross Carrying Value	$ 48,264	$ 48,254
Accumulated Amortization	(13,294)	(5,113)
Net Carrying Value	34,970	43,141
Trademarks
Balance Sheet Components [Line Items]
Gross Carrying Value	3,969	3,969
Accumulated Amortization	(992)	(382)
Net Carrying Value	2,977	3,587
Developed Technology
Balance Sheet Components [Line Items]
Gross Carrying Value	30,819	30,819
Accumulated Amortization	(5,008)	(1,926)
Net Carrying Value	25,811	28,893
Customer Relationships
Balance Sheet Components [Line Items]
Gross Carrying Value	13,466	13,466
Accumulated Amortization	(7,294)	(2,805)
Net Carrying Value	6,172	$ 10,661
Other Intangible Assets
Balance Sheet Components [Line Items]
Gross Carrying Value	10
Net Carrying Value	$ 10

Balance Sheet Components - Sc_5

Balance Sheet Components - Schedule of Future Amortization Expense of Intangible Assets (Details) $ in Thousands	Dec. 31, 2021USD ($)
Balance Sheet Components [Abstract]
2022	$ 8,182
2023	5,376
2024	3,693
2025	3,693
Thereafter	14,016
Total	$ 34,960

Balance Sheet Components - Sc_6

Balance Sheet Components - Schedule of Accrued Compensation (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Components [Abstract]
Accrued vacation	$ 1,469	$ 1,184
Accrued bonuses	1,307	831
Accrued commissions	665	828
Other accrued personnel related expenses	77	46
Total accrued compensation	$ 3,518	$ 2,889

Balance Sheet Components - Sc_7

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Components [Abstract]
Accrual for litigation	$ 7,203	$ 7,203
Accrued professional fees	974	824
Accrued sales and use taxes	657	754
Deferred rent	277	445
Accrual for inventory in transit	119	602
Contract liability	206	219
Others	1,037	157
Total accrued liabilities	$ 10,473	$ 10,204

Business Combination - Addition

Business Combination - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Nov. 30, 2021	May 11, 2020	Mar. 31, 2022	May 12, 2020	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Business acquisition, pro forma revenue							$ 44,700
Business acquisition, pro forma net loss							17,300
Revenues						$ 52,103	37,768
Bargain purchase gain							643
Reduction in transaction costs		$ 1,000
Delayed cash purchase consideration					$ 15,000		$ 15,000
Proforma adjustments for amortization of intangible assets				$ 3,100
May and September 2021 Amended Asset Purchase Agreement [Member]
Business Acquisition [Line Items]
Business combination description						(1) the timing of the delayed $15.0 million payment was deferred from May 11, 2021 to the earlier of 15 days post-IPO or November 1, 2021; (2) the timing of the $10.0 million Development Milestone payment was changed to 15 days post-IPO or, if the IPO has not been completed by November 1, 2021, upon the earlier of the closing of the Company’s first financing after November 1, 2021 or the date that the first Revenue Milestone Payment is due and it was agreed that the Development Milestone payment was achieved; and (3) the first Revenue Milestone Payment was modified from either $5.0 million if net revenue from the acquired IUH products exceeds $26.0 million in 2021 or $10.0 million if net revenue exceeds $30.0 million in 2021, to either $5.0 million if revenue from acquired IUH products in 2021 is less than $30.0 million or $10.0 million if more than $30.0 million in 2021.
First Revenue Milestone Payment [Member] | Net Revenue Less Than or Equal to $30.0 million in Calendar Year 2021 [Member]
Business Acquisition [Line Items]
Revenues						$ 30,000
Revenue milestone payment payable						$ 5,000
IUH Products [Member]
Business Acquisition [Line Items]
Revenue					$ 16,900
Revenue from contract with customer, excluding assessed tax, percentage					44.70%		44.70%
Bargain purchase gain		600
Development milestone payment		$ 10,000
Development milestone payment description						The Company is required to deliver a development-based milestone payment equal to $10.0 million, which was earned when BSC delivered into finished goods inventory the required amount of Symphion controllers, at least 50% of which fully incorporated certain design revisions (the Development Milestone). As of the acquisition date, the Company estimated that there was a 90.0% probability that the Development Milestone would be achieved within 16 months, and the earliest it would be achieved would be the end of March 2021, with May 2021 being the most likely timeframe when the Development Milestone would be achieved. The Company has agreed that this milestone was earned. The Company recorded its estimate of the fair value of the contingent consideration liability for the Development Milestone payment utilizing a discounted cash flow model to determine the present value of the expected value of Development Milestone payment. The Development Milestone was paid in November 2021 upon the completion of the Company's IPO, together with the delayed cash purchase consideration.
IUH Products [Member] | Series D Redeemable Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Business combination, share price		$ 2.06
Business combination, convertible preferred stock value		$ 2,700
IUH Products [Member] | First Revenue Milestone Payment [Member] | Forecast [Member]
Business Acquisition [Line Items]
Revenue milestone paid			$ 5,000
IUH Products [Member] | First Revenue Milestone Payment [Member] | Net Revenue Greater Than $30.0 million in Calendar Year 2021 [Member]
Business Acquisition [Line Items]
Revenues						$ 30,000
Revenue milestone payment payable						5,000
IUH Products [Member] | Second Revenue Milestone Payment [Member] | Net Revenue Exceeds $30.0 million in Calendar Year 2022 [Member]
Business Acquisition [Line Items]
Revenues						30,000
Revenue milestone payment payable						5,000
IUH Products [Member] | Second Revenue Milestone Payment [Member] | Net Revenue Greater Than $37.0 million in Calendar Year 2022 [Member]
Business Acquisition [Line Items]
Revenues						37,000
Revenue milestone payment payable						10,000
Intrauterine Health Products [Member]
Business Acquisition [Line Items]
Negative goodwill		(600)		(643)
Deferred tax liability		100		$ 132
Fair value of finished goods inventory		4,300
Fair value of raw materials inventory		3,600
Intangible assets, other than goodwill		$ 48,300
Business combination, transaction costs							$ 1,000
BSC
Business Acquisition [Line Items]
Delayed cash purchase consideration	$ 15,000
Development milestone payment	$ 10,000
General and Administrative
Business Acquisition [Line Items]
Fair value of contingent consideration						$ 400

Business Combination - Summary

Business Combination - Summary of Purchase Consideration (Details) - IUH Products [Member] $ in Thousands	May 11, 2020USD ($)
Business Acquisition [Line Items]
Closing stock consideration	$ 2,737
Cash consideration	15,000
Delayed cash consideration	15,000
Development Milestone payment	8,615
Revenue Milestone payments	15,227
Total purchase consideration	$ 56,579

Business Combination - Summar_2

Business Combination - Summary of Purchase Consideration (Parenthetical) (Details) - IUH Products [Member] - Series D Redeemable Convertible Preferred Stock [Member]	May 11, 2020$ / sharesshares
Business Acquisition [Line Items]
Number of redeemable convertible preferred stock | shares	1,331,411
Business combination, share price | $ / shares	$ 2.06

Business Combination - Schedule

Business Combination - Schedule of Purchase Price of Acquired Assets and Liabilities (Details) - Intrauterine Health Products - USD ($) $ in Thousands	May 12, 2020	May 11, 2020
Net assets acquired:
Inventory	$ 7,846
Other receivable	271
Property and equipment	999
Intangible assets, other than goodwill		$ 48,300
Warranty liability	(16)
Deferred tax liability	(132)	(100)
Negative goodwill	643	$ 600
Purchase price	56,579
Trade Names
Net assets acquired:
Intangible assets, other than goodwill	3,969
Customer Relationships
Net assets acquired:
Intangible assets, other than goodwill	13,466
Developed Technology Rights
Net assets acquired:
Intangible assets, other than goodwill	$ 30,819

Business Combination - Componen

Business Combination - Components of Identifiable Intangible Assets (Details) - Intrauterine Health Products [Member] $ in Thousands	May 12, 2020USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Value as of closing date of acquisition	$ 48,254
Trademarks [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful lives (in years)	6 years 6 months
Value as of closing date of acquisition	$ 3,969
Developed Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful lives (in years)	10 years
Value as of closing date of acquisition	$ 30,819
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful lives (in years)	3 years
Value as of closing date of acquisition	$ 13,466

Debt - Ares Term Loan - Additio

Debt - Ares Term Loan - Additional Information (Details) - USD ($)	Oct. 08, 2021	Dec. 30, 2019	Jul. 31, 2021	Jan. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Cash and cash equivalents					$ 40,608,000	$ 17,359,000
Gain (loss) on extinguishment of debt					$ (21,295,000)
Ares Term Loan
Debt Instrument [Line Items]
Debt financing						$ 31,878,000
Debt instrument advanced at closing of agreement tranche A		$ 30,000,000
Debt instrument advanced at closing of agreement tranche B		$ 10,000,000
Debt instrument advance, closing of tranche agreement date		Dec. 31, 2020
Minimum amount conditioned upon achieving in net revenues		$ 30,000,000
Debt instrument advance, closing of tranche agreement period prior to closing		12 months
Debt instrument, term					3 years
Debt instrument, maturity date					Dec. 31, 2022
Debt instrument effective interest rate	24.90%					22.70%
Prepayment premium earned percentage on principal		30.00%
Exit fees						$ 312,000
Payments of loan costs					$ 1,400,000
Interest expense on debt					4,900,000	5,600,000
Interest expense related to accretion of debt discount , debt issuance costs and exit fees					2,000,000	1,900,000
Estimated fair value of aggregate outstanding derivative instrument					0	$ 4,500,000
Ares Agreement | Ares Term Loan
Debt Instrument [Line Items]
Cash and cash equivalents					$ 5,000,000
Gain (loss) on debt modification			$ 0	$ 0
Debt instrument fixed exit fee percentage					6.25%
Derivative liability, fair value					$ 4,300,000
CIBC Agreement | Ares Term Loan
Debt Instrument [Line Items]
Debt financing	$ 32,800,000
Proceeds from repayments of debt	35,500,000
Accrued interest	100,000
Exit fees	2,600,000
Gain (loss) on extinguishment of debt	$ 4,400,000
Minimum | Ares Term Loan
Debt Instrument [Line Items]
Repayment loan percentage					4.00%
Maximum | Ares Term Loan
Debt Instrument [Line Items]
Debt financing		$ 40,000,000
Repayment loan percentage					10.00%
Payment in Kind (PIK) Note | Ares Term Loan
Debt Instrument [Line Items]
Debt instrument, periodic payment					$ 2,900,000
Payment in Kind (PIK) Note | Maximum | Ares Term Loan
Debt Instrument [Line Items]
Debt instruments accrued interest rate percentage		50.00%
Base Rate | Ares Term Loan
Debt Instrument [Line Items]
Debt instrument, interest rate terms					Borrowings under the Ares Agreement, including the Ares Loan, bear interest at either the ABR plus 8.5% per annum or the Eurodollar Rate plus 9.5% per annum, as applicable. The ABR equals the greatest of (a) 3.0%, (b) the prime rate, (c) the federal funds rate plus 0.5% and (d) the three-month Eurodollar Rate plus 1.0%. The Eurodollar Rate equals the greater of (a) 2.0% and (b) the rate per annum appearing on Bloomberg Professional Service Page BBAM1 offered rate for deposits in U.S. dollars at approximately two business days prior to the first day of such interest period for a three (3) month term; multiplied by the Statutory Reserve Rate. The Statutory Reserve Rate is based on a fraction, the numerator of which is the number one and the denominator of which is the number one minus the applicable reserve percentage for that day. Payments of interest under Ares Loan are to be made quarterly commencing on March 31, 2020.

Debt - Ares Term Loan - Schedul

Debt - Ares Term Loan - Schedule of Debt (Details) - Ares Term Loan $ in Thousands	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Principal	$ 31,878
Less: debt issuance cost and debt discount	(4,120)
Add: exit fee	312
Term loan and convertible notes	$ 28,070

Debt - Paycheck Protection Prog

Debt - Paycheck Protection Program - Additional Information (Details) - Paycheck Protection Program Loan - USD ($)	1 Months Ended		12 Months Ended
	Jun. 30, 2021	Apr. 30, 2020	Dec. 31, 2021
Debt Instrument [Line Items]
Proceeds from long term debt		$ 3,000,000
Debt instrument interest rate		1.00%
Debt instrument, term		24 months
Debt instrument payment terms			No payments were due for initial six-month period of the PPP Loan. Afterwards, payments of principal and interest were due over the following 18 months.
Gain on forgiveness of debt			$ 3,000,000
Principal Forgiveness
Debt Instrument [Line Items]
Debt instrument forgiveness	$ 3,000,000
Interest Forgiveness | Maximum
Debt Instrument [Line Items]
Debt instrument forgiveness	$ 100,000

Debt - CIBC Term Loan - Additio

Debt - CIBC Term Loan - Additional Information (Details) - USD ($)	Oct. 08, 2021	Dec. 31, 2021	Oct. 26, 2021
Debt Instrument [Line Items]
Payment of success fee		$ 400,000
CIBC Term Loan
Debt Instrument [Line Items]
Debt financing	$ 40,000,000	$ 40,000,000
Proceeds from repayments of debt	$ 35,500,000
Repayment of loan fixed rate percentage	2.50%
Debt instrument effective interest rate		6.72%
Payment of success fee	$ 400,000
Success fee derivative liability			$ 400,000
Debt instrument interest rate increase	5.00%
Payments of loan costs	$ 1,000,000
Interest expense on debt		$ 600,000
Interest expense related to accretion of debt discount , debt issuance costs and exit fees		$ 100,000
CIBC Term Loan | Minimum
Debt Instrument [Line Items]
Prepayment premium percentage	0.00%
CIBC Term Loan | Maximum
Debt Instrument [Line Items]
Prepayment premium percentage	3.00%

Debt - CIBC Term Loan - Schedul

Debt - CIBC Term Loan - Schedule of Debt (Details) - CIBC Term Loan - USD ($) $ in Thousands	Dec. 31, 2021	Oct. 08, 2021
Debt Instrument [Line Items]
Principal	$ 40,000	$ 40,000
Less: debt issuance cost and debt discount	(915)
Accrued interest	189
Term loan and convertible notes	$ 39,274

Debt - Convertible Notes - Addi

Debt - Convertible Notes - Additional Information (Details) - USD ($)	Oct. 20, 2021	Sep. 03, 2021	May 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Oct. 21, 2021	Nov. 30, 2019	May 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Debt Instrument [Line Items]
Gain (loss) on extinguishment of debt					$ (21,295,000)
Aggregate outstanding principal and accrued interest of convertible promissory notes						$ 0
Redeemable convertible preferred stock converted	19,404,066						12,397,838
Amortization of debt premium and discount					1,300,000	1,400,000
Interest expense					$ 11,728,000	12,140,000
Redeemable Convertible Preferred Stock
Debt Instrument [Line Items]
Conversion of preferred stock	7,006,228
Conversion price per share	$ 11.31
Maximum
Debt Instrument [Line Items]
Offering price per share					$ 5.61
Second Lien Loan and Security Agreements
Debt Instrument [Line Items]
Amount borrowed				$ 21,000,000		15,000,000				$ 29,200,000
2018 Note Agreements
Debt Instrument [Line Items]
Convertible notes										$ 10,000,000
Accrue interest fixed rate					8.00%
2018 Note Agreements | Maximum
Debt Instrument [Line Items]
Convertible notes											$ 20,000,000
2019 Note Agreements
Debt Instrument [Line Items]
Accrue interest fixed rate					8.00%
2019 Note Agreements | Maximum
Debt Instrument [Line Items]
Convertible notes								$ 10,500,000	$ 10,500,000
Amendment
Debt Instrument [Line Items]
Debt instrument extended maturity period				2023-06
2020 Note Agreement
Debt Instrument [Line Items]
Debt instrument, maturity date			Jun. 30, 2023
Accrue interest fixed rate					8.00%
2020 Note Agreement | Maximum
Debt Instrument [Line Items]
Convertible notes			$ 30,000,000
Amended 2018 Note Agreements, 2019 Note Agreements, and 2020 Note Agreement
Debt Instrument [Line Items]
Gain (loss) on extinguishment of debt					$ (16,900,000)
Debt instrument, maturity date		Dec. 31, 2026
Debt instrument, convertible, terms of conversion feature					to add automatic conversion of these convertible notes’ outstanding principal and accrued interest into shares of common stock if either (i) the offering price per share of our IPO is greater than $5.61 and the aggregate gross proceeds to the Company from the IPO are greater than $50.0 million or (ii) the Company receives a written request from the holders of at least 66 2/3% of the redeemable convertible preferred stock to convert all outstanding redeemable convertible preferred stock to common stock.
Amended 2018 Note Agreements, 2019 Note Agreements, and 2020 Note Agreement | Minimum
Debt Instrument [Line Items]
Offering price per share		$ 5.61
Gross proceeds from offering		$ 50,000,000
Convertible Notes
Debt Instrument [Line Items]
Interest expense					$ 6,300,000	6,500,000
Accrued interest						$ 5,100,000
Convertible Notes | Maximum
Debt Instrument [Line Items]
Debt instrument effective interest rate					6.20%	31.00%
Convertible Notes | Minimum
Debt Instrument [Line Items]
Debt instrument effective interest rate					5.00%	9.00%
Convertible Promissory Notes
Debt Instrument [Line Items]
Aggregate outstanding principal and accrued interest of convertible promissory notes	$ 79,200,000
Unamortized premium	$ 10,100,000
Estimated fair value of aggregate outstanding derivative instrument						$ 33,500,000
Accrued interest						$ 5,134,000
2020 Note Agreements
Debt Instrument [Line Items]
Deferred payment obligations additional amount to be drawn retained							$ 15,000,000

Debt - Convertible Notes - Sche

Debt - Convertible Notes - Schedule of Convertible Note (Details) $ in Thousands	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Convertible notes	$ 66,196
Convertible Note
Debt Instrument [Line Items]
Principal	69,245
Less: debt issuance costs	(38)
Less: debt discount	(8,145)
Accrued interest	5,134
Convertible notes	$ 66,196

Debt - Schedule of Contractual

Debt - Schedule of Contractual Maturities of Financing Obligations (Details) - CIBC Term Loan $ in Thousands	Dec. 31, 2021USD ($)
Debt Instrument [Line Items]
2022	$ 2,300
2023	4,457
2024	14,807
2025	14,060
2026	12,229
Total	47,853
Less: unamortized debt discounts and issuance costs	(915)
Less: interest	(7,664)
Term loan and convertible notes	$ 39,274

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details) $ in Thousands	Dec. 31, 2021USD ($)
Commitments And Contingencies Disclosure [Abstract]
2022	$ 846
2023	358
Total minimum lease payments	$ 1,204

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	Apr. 22, 2020	Jul. 27, 2018	Jul. 31, 2019	Nov. 30, 2015	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2017
Loss Contingencies [Line Items]
Operating non-cancellable lease terminate year					2023
Rent expense					$ 0.7	$ 1.1
Hologic, Inc. and Cytyc Surgical Products, LLC
Loss Contingencies [Line Items]
Loss contingency damages sought value			$ 7.1	$ 16
Loss contingency damages awarded value	$ 7.1	$ 4.8
Loss contingency accrual for potential legal losses							$ 4.8

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Deferred income tax benefit		$ 132
Valuation allowance increased	$ 13,400	4,700
Net operating loss carry forwards expire beginning year	2028
Income taxes rolling year	3 years
Unrecognized tax benefits	$ 465	$ 447	$ 431
Tax Year 2008
Operating Loss Carryforwards [Line Items]
Open tax year	2008
Tax Year 2021
Operating Loss Carryforwards [Line Items]
Open tax year	2021
Minimum
Operating Loss Carryforwards [Line Items]
Ownership percentage	5.00%
Ownership percentage increased	50.00%
Maximum
Operating Loss Carryforwards [Line Items]
Current income tax expense	$ 100
Federal
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards	$ 188,100
Income tax remain open year for examination	3 years
State
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards	$ 165,500
Income tax remain open year for examination	4 years
Research | Federal
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards	$ 1,500
Research | State
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards	$ 1,500

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation Between Federal Statutory Rate and Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal statutory rate	21.00%	21.00%
State blended rate	4.99%	3.34%
Stock-based compensation	(3.61%)	(0.77%)
Gain (loss) on debt extinguishment	(8.53%)
Other permanent items	(0.47%)	(0.13%)
Change in valuation allowance	(62.41%)	(25.48%)
Convertibel debt embedded derivative	44.95%	1.94%
Other	4.02%	0.82%
Effective tax rate	(0.06%)	0.72%

Income Taxes - Summary of Tax E

Income Taxes - Summary of Tax Effects of Temporary Differences and Carryforwards of Deferred Tax Deferred Tax and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carryforwards	$ 50,494	$ 44,568
Depreciation and amortization	4,656	3,375
Accruals and reserves	3,577	2,666
Interest expense limitation carryforward	2,229
Research and development credits	2,250	2,197
Gross deferred tax assets	63,206	52,806
Less: valuation allowance	$ (63,206)	(49,817)
Net deferred tax assets		2,989
Deferred tax liability:
Convertible debt embedded derivative		(2,989)
Total		$ 0

Income Taxes - Summary of Chang

Income Taxes - Summary of Changes in Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Gross amount of unrecognized tax benefits as of the beginning of the period	$ 447	$ 431
Increases related to current year tax provisions	18	16
Gross amount of unrecognized tax benefits as of the end of the period	$ 465	$ 447

Redeemable Convertible Prefer_5

Redeemable Convertible Preferred Stock Warrants and Common Stock Warrants - Additional Information (Details) - Series D Redeemable Convertible Preferred Stock Warrants - USD ($)	Jul. 19, 2019	May 09, 2017	Dec. 31, 2021	Oct. 21, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Number of shares of common stock issuable	43,878	33,964	77,842		77,842
Warrant expiration period	10 years	10 years
Fair value of warrants	$ 73,406			$ 400,000
Exercise price	$ 11.31	$ 11.31			$ 11.31

Redeemable Convertible Prefer_6

Redeemable Convertible Preferred Stock Warrants and Common Stock Warrants - Schedule of Share based Payment Award, Stock Options, Valuation Assumptions (Details)	Oct. 22, 2021	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividends		0.00%	0.00%
Expected volatility minimum		72.80%	61.60%
Expected volatility maximum		78.00%	75.20%
Risk-free interest rate minimum		0.60%	0.30%
Risk-free interest rate maximum		1.30%	0.70%
Series D Redeemable Convertible Preferred Stock Warrants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividends	0.00%		0.00%
Expected volatility minimum	51.40%		48.20%
Expected volatility maximum	54.70%		52.40%
Risk-free interest rate minimum	1.30%		0.60%
Risk-free interest rate maximum	1.50%		0.80%
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected warrant life		6 years	6 years
Maximum | Series D Redeemable Convertible Preferred Stock Warrants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected warrant life	7 years 8 months 12 days		8 years 7 months 6 days
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected warrant life		5 years	5 years
Minimum | Series D Redeemable Convertible Preferred Stock Warrants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected warrant life	5 years 6 months		6 years 4 months 24 days

Redeemable Convertible Prefer_7

Redeemable Convertible Preferred Stock Warrants and Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Details) - Series D Redeemable Convertible Preferred Stock Warrants - $ / shares	Jul. 19, 2019	May 09, 2017	Dec. 31, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Issuance Date	Jul. 19, 2019	May 9, 2017
Number of Shares of Common Stock Issuable	43,878	33,964	77,842	77,842
Exercise Price	$ 11.31	$ 11.31		$ 11.31
Classification	Equity	Equity
Expiration Date	Jul. 18, 2029	May 8, 2027

Redeemable Convertible Prefer_8

Redeemable Convertible Preferred Stock - Additional Information (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020VoteMember$ / sharesshares	Oct. 21, 2021$ / sharesshares	Oct. 20, 2021shares
Temporary Equity [Line Items]
Preferred stock, shares authorized	5,000,000	0	5,000,000
Preferred stock, par value | $ / shares	$ 0.001	$ 0.001	$ 0.001
Redeemable convertible preferred stock converted			12,397,838	19,404,066
Redeemable convertible preferred stock shares, issued	0	12,397,838
Redeemable convertible preferred stock shares, outstanding	0	12,397,838
Dividends declared to date | $ / shares	$ 0
Number of board of directors | Member		10
Common stock voting rights	The holders of Common Stock, voting as a separate class, shall be entitled to elect three members of the Company’s Board of Directors.
Number of voting rights | Vote		3
Temporary equity description	Each share of redeemable convertible preferred stock shall automatically be converted into fully-paid, non-assessable shares of common stock at the then effective conversion rate at the time in effect for such share immediately upon the earlier of (i) the Company’s sale of its common stock in a firm commitment underwritten public offering (public offering price of which is not less than $5.61 per share as adjusted for recapitalization, stock combinations, stock dividends, stock splits and the like) and which results in aggregate cash proceeds to the Company of at least $50,000,000 (before underwriting discounts, commissions, and fees), or (ii) upon the receipt by the Company of a written request for such conversion from the holders of at least 66 2/3% of the redeemable convertible preferred stock then outstanding voting as a single class and on an as-converted basis, or, if later, the effective date for conversion specified in such requests.
Voting rights percentage	66.67%
Minimum
Temporary Equity [Line Items]
Aggregate cash proceeds | $	$ 50,000,000
Maximum
Temporary Equity [Line Items]
Public offering price per share | $ / shares	$ 5.61
Series A Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Redeemable convertible preferred stock shares, issued		450,692
Redeemable convertible preferred stock shares, outstanding		450,692
Dividend rate | $ / shares	0.4837
Liquidation preference per share | $ / shares		$ 6.05
Series B Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Redeemable convertible preferred stock shares, issued		675,397
Redeemable convertible preferred stock shares, outstanding		675,397
Dividend rate | $ / shares	0.7110
Liquidation preference per share | $ / shares		$ 8.89
Series C Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Redeemable convertible preferred stock shares, issued		2,223,888
Redeemable convertible preferred stock shares, outstanding		2,223,888
Dividend rate | $ / shares	0.9045
Liquidation preference per share | $ / shares		$ 11.31
Series D Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Redeemable convertible preferred stock shares, issued		9,047,861
Redeemable convertible preferred stock shares, outstanding		9,047,861
Dividend rate | $ / shares	$ 0.9045
Temporary equity voting rights	The holders of Series D redeemable convertible preferred stock, voting as a separate class, shall be entitled to elect two members of the Company’s Board of Directors.
Number of voting rights | Vote		2
Liquidation preference per share | $ / shares		$ 11.31
Series A, B, C Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Temporary equity voting rights	The holders of Series A, B and C redeemable convertible preferred stock, voting as a separate classes, respectively, shall be each be entitled to elect one member of the Company’s Board of Directors.
Number of voting rights | Vote		1

Redeemable Convertible Prefer_9

Redeemable Convertible Preferred Stock - Summary of Redeemable Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Temporary Equity [Line Items]
Number of Shares Authorized	0	121,732,397
Number of Shares Issued	0	12,397,838
Number of Shares Outstanding	0	12,397,838
Carrying Value		$ 123,255
Liquidation Value	$ 0	$ 136,168
Series A
Temporary Equity [Line Items]
Number of Shares Authorized		2,725,000
Number of Shares Issued		450,692
Number of Shares Outstanding		450,692
Carrying Value		$ 2,725
Liquidation Preference per Share		$ 6.05
Liquidation Value		$ 2,725
Series B
Temporary Equity [Line Items]
Number of Shares Authorized		4,083,542
Number of Shares Issued		675,397
Number of Shares Outstanding		675,397
Carrying Value		$ 5,845
Liquidation Preference per Share		$ 8.89
Liquidation Value		$ 6,003
Series C
Temporary Equity [Line Items]
Number of Shares Authorized		13,995,537
Number of Shares Issued		2,223,888
Number of Shares Outstanding		2,223,888
Carrying Value		$ 24,980
Liquidation Preference per Share		$ 11.31
Liquidation Value		$ 25,144
Series D
Temporary Equity [Line Items]
Number of Shares Authorized		100,928,318
Number of Shares Issued		9,047,861
Number of Shares Outstanding		9,047,861
Carrying Value		$ 89,705
Liquidation Preference per Share		$ 11.31
Liquidation Value		$ 102,296

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Oct. 31, 2021	Oct. 21, 2021
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized	100,000,000	100,000,000	144,406,928		100,000,000
Aggregate intrinsic value of common stock exercised		$ 1.8
Fair value of options vested		$ 6	$ 0.6
Weighted average grant date fair value		$ 8.18	$ 0.37
Unrecognized stock-based compensation expense	$ 8.9	$ 8.9
Repurchase of common stock		0	0
Shares subject to repurchase		377,709	136,032
Aggregate exercise prices of early exercised shares		$ 0.2	$ 0.1
Common stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000	0		5,000,000
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001		$ 0.001
Unrecognized stock-based compensation expense, weighted-average recognition period		2 years 7 months 6 days
Common stock, shares reserved for issuance	1,934,095	1,934,095	67,065
Dividend yield		0.00%	0.00%
Restricted Stock Units
Subsidiary or Equity Method Investee [Line Items]
Granted		394,750
Unrecognized stock-based compensation expense	$ 1.9	$ 1.9
Unrecognized stock-based compensation expense, weighted-average recognition period		1 year
ESPP
Subsidiary or Equity Method Investee [Line Items]
Number of shares authorized for offerings	0	0
Common stock, shares reserved for issuance				401,164
2008 Stock Plan
Subsidiary or Equity Method Investee [Line Items]
Share-based Compensation arrangement by share-based payment award, award vesting period		10 years
Share based compensation arrangement by share based payment award ratably thereafter vesting period		36 months
Percentage of vesting rights		25.00%
Vesting period		1 year
2021 Plan
Subsidiary or Equity Method Investee [Line Items]
Share-based Compensation arrangement by share-based payment award, award vesting period		10 years
Share based compensation arrangement by share based payment award ratably thereafter vesting period		36 months
Percentage of vesting rights		25.00%
Vesting period		1 year
Granted	394,750
Maximum [Member]
Subsidiary or Equity Method Investee [Line Items]
Aggregate intrinsic value of common stock exercised			$ 0.1
Incremental compensation cost			$ 0.1
Maximum [Member] | 2008 Stock Plan
Subsidiary or Equity Method Investee [Line Items]
Exercise price, percent of estimated fair value of shares on date of grant		110.00%
Exercise price, percent of estimated fair market value of shares on date of grant		100.00%
Maximum [Member] | 2021 Plan
Subsidiary or Equity Method Investee [Line Items]
Exercise price, percent of estimated fair value of shares on date of grant		110.00%
Exercise price, percent of estimated fair market value of shares on date of grant		100.00%
Minimum | 2008 Stock Plan
Subsidiary or Equity Method Investee [Line Items]
Estimated fair value shares date of grant		10.00%
Minimum | 2021 Plan
Subsidiary or Equity Method Investee [Line Items]
Estimated fair value shares date of grant		10.00%

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) - Schedule of Shares Reserved for Future Issuance (Details) - shares	Dec. 31, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Warrants to purchase redeemable convertible preferred stock		77,842
Warrants to purchase common stock	77,842
Common stock options issued and outstanding	2,175,685	2,466,594
Common stock available for future grants	1,934,095	67,065
Restricted stock units issued and outstanding	394,750
ESPP
Class Of Stock [Line Items]
Convertible notes	401,164
Series A Redeemable Convertible Preferred Stock Outstanding
Class Of Stock [Line Items]
Convertible preferred stock reserved for future issuance		450,692
Series B Redeemable Convertible Preferred Stock Outstanding
Class Of Stock [Line Items]
Convertible preferred stock reserved for future issuance		675,397
Series C Redeemable Convertible Preferred Stock Outstanding
Class Of Stock [Line Items]
Convertible preferred stock reserved for future issuance		2,223,888
Series D Redeemable Convertible Preferred Stock Outstanding
Class Of Stock [Line Items]
Convertible preferred stock reserved for future issuance		9,047,861

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Number of Shares Underlying Outstanding Options, Beginning balance	2,466,594	2,482,957
Number of Shares Underlying Outstanding Options, Granted	1,846,375	451,689
Number of Shares Underlying Outstanding Options, Exercised	(1,975,918)	(282,813)
Number of Shares Underlying Outstanding Options, Forfeited or Cancelled	(161,366)	(185,239)
Number of Shares Underlying Outstanding Options, Ending balance	2,175,685	2,466,594	2,482,957
Number of Shares Underlying Outstanding Options, Shares Exercisable	1,502,978
Number of Shares Underlying Outstanding Options, Vested and Expected to Vest	2,175,685
Weighted Average Exercise Price, Outstanding beginning balance	$ 0.61	$ 2.96
Weighted Average Exercise Price, Options granted	11.05	0.61
Weighted Average Exercise Price, Options exercised	0.61	0.73
Weighted Average Exercise Price, Options forfeited or cancelled	3.28	1.28
Weighted Average Exercise Price, Oustanding ending balance	9.27	$ 0.61	$ 2.96
Weighted Average Exercise Price, Shares exercisable	9.32
Weighted Average Exercise Price, vested and expected to vest	$ 9.27
Weighted Average Remaining Contractual Term (in years), Outstanding	8 years 8 months 4 days	5 years 2 months 15 days	5 years 7 months 2 days
Weighted Average Remaining Contractual Term (in years), Shares exercisable	8 years 4 months 24 days
Weighted Average Remaining Contractual Term (in years), Vested and Expected to Vest	8 years 8 months 4 days
Aggregate Intrinsic Value, Outstanding	$ 2,856		$ 2,257
Aggregate Intrinsic Value, Shares exercisable	2,066
Aggregate Intrinsic Value, Vested and expected to vest	$ 2,856

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) - Schedule of Restricted Stock Units (Details) - Restricted Stock Units	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares Underlying Outstanding Restricted Stock, Granted | shares	394,750
Number of Shares Underlying Outstanding Restricted Stock, Unvested, Ending Balance | shares	394,750
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 5.17
Weighted Average Grant Date Fair Value, Unvested, Ending Balance | $ / shares	$ 5.17

Stockholders' Equity (Deficit_6

Stockholders' Equity (Deficit) - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Stock-based compensation expense	$ 6,817	$ 858
Cost of Goods Sold
Class Of Stock [Line Items]
Stock-based compensation expense	274	132
Sales and Marketing
Class Of Stock [Line Items]
Stock-based compensation expense	2,137	311
Research and Development
Class Of Stock [Line Items]
Stock-based compensation expense	136	10
General and Administrative
Class Of Stock [Line Items]
Stock-based compensation expense	4,270	405
Stock Options
Class Of Stock [Line Items]
Stock-based compensation expense	6,722	$ 858
RSU
Class Of Stock [Line Items]
Stock-based compensation expense	$ 95

Stockholders' Equity (Deficit_7

Stockholders' Equity (Deficit) - Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility minimum	72.80%	61.60%
Expected volatility maximum	78.00%	75.20%
Risk-free interest rate minimum	0.60%	0.30%
Risk-free interest rate maximum	1.30%	0.70%
Dividend yield	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	5 years	5 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years	6 years

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Numerator
Net loss attributable to common stockholders	$ (21,464)	$ (18,263)
Denominator:
Weighted-average common shares outstanding	7,012,226	968,648
Net loss per share attributable to common stockholders, basic and diluted	$ (3.06)	$ (18.85)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		12,397,838
Redeemable Convertible Preferred Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		77,842
Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	77,842
Unvested Early Exercised Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	377,709	136,032
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,175,685	2,466,594
RSU
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	394,750

Net Loss Per Share Attributab_5

Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Earnings Per Share [Abstract]
Conversion of 2018, 2019 and 2020 Notes into common stock upon initial public offering	$ 0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - Apical Instruments Inc - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Fees charged		$ 200,000
Maximum
Related Party Transaction [Line Items]
Related party transaction amount owned		$ 100,000
Fees charged	$ 100,000
Board of Directors
Related Party Transaction [Line Items]
Percentage of interest owned	100.00%